var title_f28_20_28992="Relapsing polychondritis CT";
var content_f28_20_28992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of the chest in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT during inspiration (panel A) and expiration (panel B) in a patient with relapsing polychondritis. The trachea (panel A) and the proximal bronchi (arrow in B) show mild diffuse wall thickening and luminal narrowing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28992=[""].join("\n");
var outline_f28_20_28992=null;
var title_f28_20_28993="Osteoarthritis PI";
var content_f28_20_28993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bones that meet at a joint usually do not rub against each other because they are covered by a rubbery material called cartilage. In people with osteoarthritis, the cartilage wears away, and the bones can grind against each other. Sometimes the bones also form spurs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28993=[""].join("\n");
var outline_f28_20_28993=null;
var title_f28_20_28994="Plasma protein fraction: Drug information";
var content_f28_20_28994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Plasma protein fraction: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Plasmanate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Volume expansion:",
"     </b>",
"     I.V.: Usual minimum dose: 250-500 mL; adjust dose based on response",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [human, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasmanate&reg;: 5% (50 mL, 250 mL) [contains albumin (human), potassium 0.25 mEq/L, sodium 145 mEq/L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration. Administration should begin within 4 hours after entering the container; rapid infusion may cause vascular overload. Hypotension may occur when administered at rates &gt;10 mL/minute; decrease rate of infusion if hypotension occurs",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma volume expansion and maintenance of cardiac output in the treatment of certain types of shock or impending shock",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5146606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Edema, flushing, hypotension (related to rate of infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5143475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to plasma protein fraction or any component of the formulation; patients on cardiopulmonary bypass; severe anemia; congestive heart failure; increased blood volume",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5143476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: Rapid infusions may cause hypotension. Decrease or stop infusion if sudden hypotension occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. May be useful for initial therapy of shock due to dehydration or infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coagulation disorders: Plasma protein fraction does not contain coagulation factors and does not correct coagulation disorders.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5143474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9843048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Plasmanate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (50 mL): $23.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5146612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Blood pressure, pulse, pulmonary exam",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Plasma Proteinlosung 5% (AT);",
"     </li>",
"     <li>",
"      Plasma-Protein-Fraktion (DE);",
"     </li>",
"     <li>",
"      Plasmanate (HK, ID, MY);",
"     </li>",
"     <li>",
"      Plasmatein (HK, MY, PH);",
"     </li>",
"     <li>",
"      Protenate (HK, ID, TW)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10217 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28994=[""].join("\n");
var outline_f28_20_28994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210763\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210767\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210764\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210765\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210750\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210759\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210758\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5146606\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5143475\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5143476\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299888\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222370\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210754\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5143474\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9843048\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323701\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5146612\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875319\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10217|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_20_28995="Low atrial isolation";
var content_f28_20_28995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ablation lesions and lead placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolation of small atrial segment surrounding the atrioventricular node and the His bundle was achieved by sequential radiofrequency ablation. The structures around the Koch triangle in the swine heart are shown here. The relative location of the CS and the IVC is different from that in humans. Please see text for details. The location of the tricuspid annulus is labeled. In this study, the His bundle is mapped first. The atrioventricular node is presumably just proximal and inferior to the His bundle. The small atrial segment surrounding the atrioventricular node and the His bundle is isolated using a series of radiofrequency ablation lesions. The isolation is started with a line crossing the CS-tricuspid isthmus, which is extended superiorly along the anterior edge of the CS. A pacing lead is inserted into the isolated atrial segment surrounded by the ablation lines, the tricuspid annulus, and the atrioventricular node-His bundle. The results of this study are not dependent on the location of the lead implantation (either closer to the AV node or closer to the CS-tricuspid isthmus).",
"    <div class=\"footnotes\">",
"     The circles labeled as A.B.L.A.T.I.O.N.L.I.N.E. represent the linear ablation lesions.",
"     <br>",
"      Attain: steerable guiding sheath; AVN: location of the atrioventricular node; CS: coronary sinus; HB: the location of the His bundle; IVC: inferior vena cava.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lu F, Laizzo PA, Benditt DG, et al. Isolated atrial segment pacing: an alternative to his bundle pacing after atrioventricular junctional ablation. J Am Coll Cardiol 2007; 49:1443. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28995=[""].join("\n");
var outline_f28_20_28995=null;
var title_f28_20_28996="Flail chest injury";
var content_f28_20_28996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Flail chest injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28996=[""].join("\n");
var outline_f28_20_28996=null;
var title_f28_20_28997="Liposomal doxorubicin: Patient drug information";
var content_f28_20_28997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal doxorubicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     see \"Liposomal doxorubicin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15125198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doxil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Caelyx&reg;;",
"     </li>",
"     <li>",
"      Myocet&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease you may need a lower dose. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have unsafe allergic effects or bad side effects during the infusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may irritate the vein. It may burn the skin if the drug leaks from the vein when it is given. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxorubicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had daunorubicin, doxorubicin, epirubicin, or idarubicin before, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or irritation of the palms of hands or soles of feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to orange or red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin on hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11357 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28997=[""].join("\n");
var outline_f28_20_28997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163252\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021201\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021203\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021202\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021207\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021208\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021210\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021205\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021212\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=related_link\">",
"      Liposomal doxorubicin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_20_28998="Histopathology Aspergillus spp";
var content_f28_20_28998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histopathologic examination of Aspergillus species",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Special stains for histopathologic examination of aspergillus species (eg, periodic acid-Schiff or methenamine silver stain) demonstrate septate hyphae with characteristic acute angle branching (see arrows). Invasive disease is diagnosed when these hyphae are found to be eroding into tissue structures, in this case an ocular tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John W Baddley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28998=[""].join("\n");
var outline_f28_20_28998=null;
var title_f28_20_28999="Sonogram pt on tamoxifen";
var content_f28_20_28999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70071%7EOBGYN%2F62592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70071%7EOBGYN%2F62592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal pelvic sonogram of a patient treated with tamoxifen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central uterine echo measured 18 mm and is heterogeneous in its appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline infusion sonohysterography of a patient on tamoxifen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrium surrounding the fluid is thin and atrophic and small sonolucent microcystic changes (marked by calipers) are seen under the superficial epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_28999=[""].join("\n");
var outline_f28_20_28999=null;
var title_f28_20_29000="Overview of treatment for inguinal and femoral hernias";
var content_f28_20_29000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment for inguinal and femoral hernias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29000/contributors\">",
"     David C Brooks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29000/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29000/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/20/29000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernias are areas of weakness or frank disruption of the fibromuscular tissues of the body wall through which intracavity structures pass. They are among the oldest recorded afflictions of man, and inguinal hernia repair is the most common general surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgery is the only effective treatment; however, the optimal therapeutic procedure is controversial.",
"   </p>",
"   <p>",
"    Femoral hernias account for less that 10 percent of all groin hernias, but have a higher risk of incarceration or strangulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/2\">",
"     2",
"    </a>",
"    ]. Hernias of shorter duration, both inguinal and femoral, also carry an increased risk of strangulation.",
"   </p>",
"   <p>",
"    An overview of the treatment of groin hernias is presented here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of groin hernias, inguinal hernias in children, and abdominal wall hernias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGERY VERSUS WATCHFUL WAITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive treatment of all hernias, regardless of their origin or type, is surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/1\">",
"     1",
"    </a>",
"    ]. Outcomes are generally excellent with minimal short-term morbidity and rapid return to presurgical health. This is true even in elderly individuals, especially with the use of local anesthesia.",
"   </p>",
"   <p>",
"    These surgical outcomes combined with limited outcome data in patients who do not undergo surgery have led to recommendations to offer surgery to most patients with a groin hernia, regardless of symptoms. The risks of delayed surgery are primarily related to the risk of incarceration and strangulation, which are the only true medical indications for repair of hernias. However, it is not possible to identify with any degree of reliability which hernias are likely to incarcerate or strangulate versus those that will remain uncomplicated. In a retrospective review of 1034 consecutive patients with a groin hernia, patients requiring acute hernia repair (n = 63) were significantly more likely than those having elective repair to have a femoral hernia (7.4 versus 2.5 percent), scrotal hernia (32.4 versus 16.2 percent), or recurrent hernia (30.9 versus 16.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/3\">",
"     3",
"    </a>",
"    ]. Of those undergoing acute repair, 33 patients (52 percent) were not previously diagnosed and 5 patients (17 percent) with a known hernia were asymptomatic and watchfully observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of incarceration is greatest soon after the hernia manifests itself. In one series of 439 inguinal hernias, the cumulative probability of strangulation was 2.8 percent at three months; the cumulative probability at two years was 4.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/4\">",
"     4",
"    </a>",
"    ]. The likelihood of incarceration also decreases as the hernia increases in size since it is less likely that intestinal or visceral contents will become caught within a large sac.",
"   </p>",
"   <p>",
"    While surgery is clearly indicated for most patients with significant symptoms related to a hernia, it may be reasonable to delay surgery in patients with inguinal hernia who have minimal or no symptoms. The largest study evaluating the strategy of \"watchful waiting,\" the WW trial, randomly assigned 720 men with an inguinal hernia to a strategy of watchful waiting or open tension-free hernia repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/5\">",
"     5",
"    </a>",
"    ]. The men were at least 18 years of age (the majority were between the ages of 40 to 65), and were either asymptomatic or had only minimal symptoms (eg, absence of hernia-related pain or discomfort limiting usual activities, and no difficulty in reducing the hernia within six weeks of screening). The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years follow-up, there was no difference between the two groups in the primary end points of pain sufficient to limit activity or change in physical health scores.",
"     </li>",
"     <li>",
"      Twenty-three percent of patients in the watchful waiting group had surgery within two years and 31 percent at four years. The rate of complications was not significantly different between patients who were assigned to and received surgical repair and those who were assigned to watchful waiting and then crossed over to receive surgical repair (21.7 versus 27.9 percent).",
"     </li>",
"     <li>",
"      Significant hernia complications are rare but can occur in patients being watched. Overall, there were 0.0018 hernia-related adverse events per patient-year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A smaller study (160 men), published subsequent to the WW trial, also found no difference in the rate of hernia accidents and pain scores between the surgery and watchful waiting groups, although patients who had immediate surgery responded that their general health had improved at one year, compared to a perception of health decline in the observation group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients in both studies were white men over the age of 40 with inguinal hernia. Thus, it is not clear whether these results are applicable to younger patients, women, other ethnic groups, or patients with non-inguinal hernias. Nevertheless, these findings suggest that a strategy of watchful waiting rather than referral for surgery can be considered in patients with asymptomatic or minimally symptomatic inguinal hernia, as long as they are aware of the risk, albeit small, of hernia complications and understand the need for prompt medical attention should symptoms of these complications occur. Although most authors agree that watchful waiting is a safe therapeutic option, some authors suggest elective surgery, rather than watchful waiting, for patients who are elderly, who have limited access to emergency care, or significant illness that would put them at greater risk for poor outcome after bowel strangulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Femoral hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral hernias account for 2 to 4 percent of groin hernias, are more common in women, and are more apt to present with strangulation and require emergency surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/8\">",
"     8",
"    </a>",
"    ]. The Swedish Hernia Register documented 3980 femoral hernia repairs (2524 elective and 1409 emergent) between 1992 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/8\">",
"     8",
"    </a>",
"    ]. Femoral hernia operations accounted for 23 percent of groin hernia operations in women, as compared with 1 percent in men. The repairs were done as emergencies in women 40 percent of the time as compared with 28 percent for men. Bowel resection was required in 23 percent of emergent femoral hernia repairs, but only 0.6 percent of elective repairs. Additionally, the risk of mortality for emergency operations was significantly higher than for elective operations (OR 5.37, 95% CI 3.24-8.91). This study highlights the importance of repairing femoral hernias in an elective setting and suggests that watchful waiting is not a prudent strategy in patients with femoral hernias, even those who are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2018164283\">",
"    <span class=\"h2\">",
"     Use of a truss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only nonsurgical therapy for groin hernias is use of a truss, a device consisting of a strap similar to an athletic supporter with a metal or hard plastic plug that is positioned to lie over the defect. The hard disc or plug presses inwardly, reducing the contents of the hernia back into the abdomen.",
"   </p>",
"   <p>",
"    There are insufficient data to determine the efficacy of trusses in controlling symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. In addition, the truss is potentially detrimental; if the hernia contents protrude while the truss is in place, the truss may constrict the bowel or other hernia contents to such a degree that they are injured. Furthermore, prolonged use of a truss can lead to atrophy of the spermatic cord or fusion to the hernial sac and atrophy or deterioration of the fascial margins, making surgical repair more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, use of a truss may be appropriate in rare situations but is generally discouraged",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2018164484\">",
"    <span class=\"h1\">",
"     STRANGULATED HERNIA REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency surgery within four to six hours may prevent loss of bowel from a strangulated hernia. When bowel perforation has occurred due to necrosis from prolonged strangulation, the Shouldice operative technique is recommended. Mesh should not be used when there is gross contamination, but may be considered where contamination is minimal and broad-spectrum antibiotics administered during and for several days following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2018164221\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernia repair can be performed using general, regional (spinal or epidural), or local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/11\">",
"     11",
"    </a>",
"    ]. Laparoscopic repairs using the IPOM or TAPP approach require general anesthesia and its attendant risks. TEP repairs are often done under general anesthesia, but can be performed under spinal or epidural anesthesia. General anesthesia may be used for the open approach, but it is generally not favored unless the patient has a compelling desire to be completely anesthetized.",
"   </p>",
"   <p>",
"    Open repairs of inguinal or femoral hernias are most commonly performed using spinal anesthesia, continuous epidural anesthesia, or local anesthesia with or without sedation. Local anesthesia with sedation is referred to as monitored anesthesia care (MAC). It has the advantages of being completely controllable, not requiring prolonged postoperative observation, and being simple and easy to perform. The major disadvantage of local anesthesia is that it may be inadequate anesthesia for large hernias.",
"   </p>",
"   <p>",
"    Local anesthesia can also be performed without sedation. This is suitable only for particularly motivated individuals who are not obese. The advantages of the sedative component of MAC anesthesia are that it can be individualized to the patient's specific desires for wakefulness and can be rapidly reversed at the end of the case. The patient must always be accompanied upon leaving the surgical suite if sedation is used.",
"   </p>",
"   <p>",
"    Local anesthesia can be administered in two ways: as a nerve block of the ilioinguinal and iliohypogastric nerves or as direct infiltration into the proposed incision site. The former may be more difficult to achieve, but has the advantage of not causing significant soft tissue edema. Epinephrine can be added to the local anesthetic at the surgeon's discretion, but it is often omitted in patients with significant cardiac risks.",
"   </p>",
"   <p>",
"    Spinal or continuous epidural anesthesia provides reliable anesthesia and allows the surgeon a greater amount of maneuverability since the anesthetized area is significantly larger than the operative field. Disadvantages include incomplete anesthesia, prolonged anesthesia, urinary retention, hypotension, spinal headache, and a longer time in the recovery area.",
"   </p>",
"   <p>",
"    A randomized trial of local, regional, and general anesthesia in 616 adult patients in 10 hospitals undergoing open inguinal hernia repair found that local anesthesia was superior in the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients who received local anesthesia had less postoperative pain and nausea, shorter time spent in the hospital (3.1 versus 6.2 hours with regional and general anesthesia), and fewer unplanned overnight admissions (3 versus 14 and 22 percent, respectively). Another multicenter randomized trial compared spinal and local anesthesia in 100 patients undergoing open hernia repair and also found local anesthesia was associated with less postoperative pain, shorter operating time, and fewer overnight stays [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INGUINAL HERNIA REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most contentious aspect of inguinal hernia repair is the debate between proponents of the traditional open procedure and those who favor a laparoscopic approach (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/14\">",
"     14",
"    </a>",
"    ]. The major difference between the two techniques is that the open procedure is performed anterior to the defect, while the laparoscopic approach performs the repair posterior to the defect.",
"   </p>",
"   <p>",
"    Regardless of the technique employed, successful surgical therapy is most often associated with a tension-free repair of the defect to decrease the recurrence rate. Past efforts to suture the defect closed resulted in unacceptably high recurrence rates, sometimes as high as 15 percent.",
"   </p>",
"   <p>",
"    Modern techniques accomplished this goal by placing mesh over the defect, or in the case of the laparoscopic approach, behind the defect. The only currently available repair that does not utilize mesh and has an acceptably low recurrence rate is the Shouldice repair, which is discussed in the next section.",
"   </p>",
"   <p>",
"    An important additional advantage of tension-free repairs is that they cause significantly less short-term pain and discomfort. This allows patients a more rapid return to activities of daily living.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Open repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data comparing the recurrence rate of open mesh versus open non-mesh techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/12\">",
"     12",
"    </a>",
"    ]. An attempted meta-analysis concluded that mesh repair was associated with fewer recurrences, although the authors admitted that formal meta-analysis was limited by the lack of available study data [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/15\">",
"     15",
"    </a>",
"    ]. A review of 26,304 herniorrhaphies performed in Denmark published after the meta-analysis found that mesh repairs had a lower reoperation rate than conventional open repairs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polypropylene woven mesh (marketed under a variety of names such as Marlex, Prolene, SurgiPro) is preferred to other prosthetic materials for repair of inguinal and femoral hernias. Expanded polytetrafluoroethylene (ePTFE or Gore-Tex) is an alternative that has not gained wide acceptance for groin hernias but is used extensively for incisional hernias. This material does not provoke a significant reaction when placed directly over the serosal surfaces of bowel; this inflammatory reaction and the subsequent fibrosis that develops is believed to be necessary for a strong repair in the groin.",
"   </p>",
"   <p>",
"    Polypropylene mesh is the standard component of both primary and recurrent hernia repairs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/17\">",
"     17",
"    </a>",
"    ]. The two most common open prosthetic repairs are the Lichtenstein [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/18\">",
"     18",
"    </a>",
"    ] and the \"plug and patch\" repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The Kugel repair places the mesh in a properitoneal position, rather than anterior to the transversus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/21\">",
"     21",
"    </a>",
"    ]. Details of open surgical repair are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Shouldice technique is commonly used for open repair of inguinal hernias that are performed without mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/22\">",
"     22",
"    </a>",
"    ]. This technique involves division of all layers of the floor of the canal followed by reconstruction in a four layer overlap technique utilizing continuous fine wire sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/23\">",
"     23",
"    </a>",
"    ]. This allows the defect to be closed with multiple layers, none of which are placed with inordinate tension. This completely obliterates the defect in the canal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shouldice and colleagues have reported recurrence rates of less than 2 percent using this technique in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/24\">",
"     24",
"    </a>",
"    ]. Their results have not been equaled by any non-prosthetic repair, and recurrence rates this low have not been achieved by other surgeons. The recurrence rate depends upon the level of surgical expertise; in one report of 183 inguinal hernias repaired under local anesthesia, the recurrence rates for beginners (less than six repairs under local anesthesia) versus more experienced surgeons were 9.4 and 2.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laparoscopic repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of laparoscopic repair procedures: Laparoscopic hernia repairs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26393?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Laparoscopic techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The completely extraperitoneal (TEP) repair is performed in the preperitoneal, rather than the peritoneal, space [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. The surgeon develops a space between the peritoneum and the anterior abdominal wall so that the peritoneum is never violated. In experienced hands, this approach has the advantage of eliminating the risk of intraabdominal adhesion formation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The transabdominal properitoneal patch (TAPP) repair involves the placement of mesh in a preperitoneal position, which is covered by peritoneum. This keeps the mesh away from the bowel. The advantages of the TAPP are that it does not leave intraperitoneal mesh and a larger piece of mesh is used [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laparoscopic versus open repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proponents of laparoscopic hernia repair cite advantages such as reduced postoperative pain, and early return to normal activity. However, serious complications have also been reported, including nerve and major vascular injury, bowel obstruction, and bladder injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/30\">",
"     30",
"    </a>",
"    ]. Additionally, performance of a laparoscopic repair may be technically challenging if the patient has had prior prostatic surgery. Similarly, performance of a TEP may make future prostatic surgery more difficult.",
"   </p>",
"   <p>",
"    Systematic reviews of this topic have generally concluded that while laparoscopic repair is indeed associated with less postoperative pain and more rapid return to normal activities (including work), it takes longer to perform and may increase the risk of rare, but serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. A cost-effectiveness analysis found that laparoscopic repair is associated with high incremental costs per quality-adjusted life years (QALYs) gained, although sensitivity analyses showed that there are specific situations in which laparoscopic repair may be a viable alternative, such as when reusable equipment is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/34\">",
"     34",
"    </a>",
"    ]. A study that investigated quality of life outcomes found that open repair was associated with at least as good, if not better outcomes, than laparoscopic repair.",
"   </p>",
"   <p>",
"    A large, multicenter trial performed subsequent to the above systematic reviews included 1983 patients randomly assigned to an open mesh or laparoscopic mesh repair and came to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients treated laparoscopically had less pain on the day of surgery and at two weeks, and returned to work one day earlier. Laparoscopic repair resulted in significantly more recurrences at two years (10.1 versus 4.9 percent) and was associated with more complications (39 versus 33.4 percent) including more life-threatening complications (1.1 versus 0.1 percent). Primary hernia repair by laparoscopy resulted in more recurrences than open repair (10.1 versus 4.0 percent) but had similar recurrence rates to open repair when performed for treatment of recurrent hernias (10.0 versus 14.1 percent). Surgeons who had performed more than 250 laparoscopic repairs had half the rate of recurrence of surgeons who had performed fewer repairs; no similar association with experience was seen for the simpler open repairs. Unlike some earlier trials that found lower recurrence rates with laparoscopic repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/36\">",
"     36",
"    </a>",
"    ], all the open repairs in this trial were performed as tension-free repairs with mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients were older (average age 58) and less healthy (only 34 percent were ASA class I) than the general population.",
"   </p>",
"   <p>",
"    Laparoscopic repair may be advantageous in returning patients who perform heavy manual labor to work earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/38\">",
"     38",
"    </a>",
"    ], and open repair may be particularly advantageous in an older, less healthy population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/35\">",
"     35",
"    </a>",
"    ]. Open repair, as with laparoscopic repair, generally does not require overnight hospital stay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FEMORAL HERNIA REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two different approaches to femoral hernia repair depending upon the size of the hernia. The simplest approach is anterior to the inguinal ligament and caudad towards the upper aspect of the leg. The hernia sac and contents can often be found at this location, dissected, and reduced if the sac is small. The defect can then be repaired with mesh or direct suture. If the defect is particularly small, the contents of the sac (eg, fat) may have to be resected to reduce the hernia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link&amp;anchor=H22#H22\">",
"     \"Inguinal and femoral hernia repair: Open techniques\", section on 'Femoral hernias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a large volume of intraabdominal contents has protruded into the sac or if there is bowel in the defect, the best approach may be from the preperitoneal aspect of the inguinal canal. The transversus abdominis and transversalis fascia are divided and any intraabdominal contents are removed from the hernia. In addition, this approach allows the surgeon to inspect the bowel and insure its viability, which is important if a strangulated hernia is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECUPERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes of inguinal hernia repair are generally excellent.",
"   </p>",
"   <p>",
"    Patients in sedentary employment generally may return to work within 10 days of surgery; those involved in manual labor should refrain from heavy lifting (&gt;25 pounds) for approximately four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/39\">",
"     39",
"    </a>",
"    ]. One small study that examined reaction times in an emergency stop simulation suggested that driving can resume 10 days following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time period before the patient can return to work following open or laparoscopic hernia repair is typically brief, but depends upon many factors, including type of procedure, motivation, and employment status. As an example, one study found that the number of days off work was longer for patients receiving workers' compensation compared to those with commercial insurance (34 versus 13 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/41\">",
"     41",
"    </a>",
"    ]. Another randomized series reported patients not receiving worker's compensation had a shorter convalescence after laparoscopic than after open herniorrhaphy (8 and 11 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGICAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecchymosis and bruising are common accompaniments to groin hernia surgery. The type of hernia repair affects the complications that occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are uncommon postoperative complications. Skin flora are the most prominent etiologic organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11268?source=see_link\">",
"     \"Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of seven randomized trials of antibiotic prophylaxis for open inguinal hernia repair found pooled risks of infection in the prophylaxis and placebo groups of 3.1 and 4.7 percent, respectively (odds ratio [OR] 0.61, 95% CI 0.32-1.17) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/42\">",
"     42",
"    </a>",
"    ]. Although this reduction in infection risk was not statistically significant, many surgeons routinely administer antibiotics prior to surgery. However, with the increasing problem of antibiotic resistance and low incidence of infection, this practice cannot be recommended. An additional argument for avoiding prophylactic antibiotics is that most inguinal hernia wound infections can be easily treated with a brief course (five to seven days) of an oral cephalosporin.",
"   </p>",
"   <p>",
"    Patients undergoing mesh repair are at slightly higher risk of developing an infection. A meta-analysis of six randomized trials involving 2500 patients found that patients receiving prophylactic antibiotics had half the number of surgical site infections (1.38 versus 2.89 percent, OR 0.48, 95% CI 0.27-0.85) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/43\">",
"     43",
"    </a>",
"    ]. Most patients who develop a wound infection, even if polypropylene mesh is present, can be successfully treated by aggressive antibiotic treatment without the need to remove the prosthetic material [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Seromas and hematomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seromas and hematomas are not infrequent complications after anterior hernia repair. They occur either because a dead space was left in place of a large hernia sac that was reduced or because of bleeding or fluid collection in the subcutaneous space upon or after closure. In the randomized trial of surgery versus watchful waiting cited above, 6.1 percent of patients undergoing surgery with an open mesh repair developed a wound hematoma, 4.5 percent developed a scrotal hematoma, and 1.6 percent developed a seroma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defined fluid collections infrequently require drainage or aspiration; most will either resolve on their own or, in the case of some hematomas, spontaneously decompress through the wound. This can be unsettling to the patient but is not a serious complication.",
"   </p>",
"   <p>",
"    A pseudohernia can develop after a laparoscopic hernia repair. This occurs if a large hernia sac is not completely removed and subsequently fills with fluid or blood in the early post-operative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Persistent groin pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of persistent pain following hernia repair has been reported between 0 and 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Up to 50 percent of patients report some degree of residual groin pain at one year of follow-up, but 5 to 25 percent complain of moderate to severe and possibly disabling pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/45,47-50\">",
"     45,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a survey of 2500 Swedish patients two to three years after primary surgery for groin hernia, 30 percent reported some residual groin pain, and 11 to 14 percent reported that the pain interfered with activities (sitting, walking) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/51\">",
"     51",
"    </a>",
"    ]. Risk factors for postoperative pain were preoperative pain and occurrence of postoperative complications. Anterior hernia repairs were associated with more pain than laparoscopic and open posterior operations, though interpretation of these findings is limited by the observational nature of the data (eg, patients were not randomly assigned to a specific procedure).",
"   </p>",
"   <p>",
"    The nature of persistent pain may change with time. A prospective study that included 781 elective primary hernia repairs found 40 percent of patients experienced pain preoperatively, 16 percent at six months after a Lichtenstein or Shouldice repair, and 16 percent after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/52\">",
"     52",
"    </a>",
"    ]. For patients who were pain-free preoperatively (n = 355), 53 (15 percent) developed chronic pain. Of that cohort, 33 patients (65 percent) had pain at six months but not at five years, 16 patients (30 percent) had pain at six months and five years, and 36 patients (69 percent) were asymptomatic at six months but had pain at five years. Significant predictors of persistent pain included preoperative pain compared with no preoperative pain (22 versus 13 percent), strong early postoperative pain compared with lesser pain (28 versus 15 percent), preoperative sensory disorder (35 versus 13 percent), and iliohypogastric nerve neurectomy compared with preservation (34 versus 15 percent).",
"   </p>",
"   <p>",
"    Persistent pain following inguinal hernia repair may be due to neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/45,53\">",
"     45,53",
"    </a>",
"    ]. Neuralgia is due to injury or entrapment of any of the named sensory nerves that innervate the groin (ilioinguinal, iliohypogastric, genital branch of the genitofemoral, lateral femoral nerves) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/45\">",
"     45",
"    </a>",
"    ]. The ilioinguinal and genitofemoral nerves are most commonly injured during open surgery, while the lateral femoral nerve of the thigh is more commonly injured during laparoscopic repairs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hernia recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernia recurrence occurs in 0.5 to 15 percent of patients. The frequency of recurrent hernias after surgery is a function of the type of hernia repair initially performed, the comorbidities of the patient, and the length of time from the original hernia repair. As mentioned above, open mesh procedures may be associated with a lower recurrence risk than non-open mesh procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/15\">",
"     15",
"    </a>",
"    ]. In the randomized trial of surgery versus watchful waiting cited above, less than 2 percent of patients had a recurrence at two years follow-up after an open mesh repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29000/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hernia recurrences can be broken down into three functional time periods:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate",
"     </li>",
"     <li>",
"      Greater than six months and up to five years from the repair",
"     </li>",
"     <li>",
"      Late recurrences beyond five years from the repair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immediate breakdown is felt to be due to biomaterial breakdown or patient overactivity, intermediate recurrences appear related to technical (surgeon) factors, and late recurrence is due to the natural history of biology and aging. The rate of recurrent groin hernias in the early to middle postoperative period can be minimized by avoiding infection, undue tension, and devascularizing tissues. In addition, specific recommendations such as weight loss in obese patients, cessation of smoking, and discontinuation of steroid therapy, if possible, will decrease the potential for hernia recurrence.",
"   </p>",
"   <p>",
"    The use of prosthetic material has dramatically diminished the earliest recurrences, but poor fixation, excessive dissection, and devascularization can lead to recurrences of the second type. Late recurrences continue to occur, but at a slightly decreased incidence.",
"   </p>",
"   <p>",
"    Another type of \"recurrence\" occurs if the surgeon does not perform an adequate examination of all potential hernia sites at the time of the initial surgery. This can lead to an unidentified hernia later presenting as a so-called \"recurrence.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only effective treatment for hernias is surgery, and patients with significant symptoms related to their hernia should be referred for surgical repair. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using a truss in lieu of surgery, except for rare situations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2018164283\">",
"       'Use of a truss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that most asymptomatic and minimally symptomatic patients with inguinal hernia undergo elective surgical repair (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Patients who wish to avoid surgery can reasonably be treated with watchful waiting. Watchful waiting rather than surgical referral is an appropriate option in patients with an asymptomatic or minimally symptomatic inguinal hernia, as long as they are aware of the small risks of hernia complications (incarceration and strangulation) and understand the need for prompt medical attention should symptoms of these complications occur. The risk of incarceration is highest soon after the hernia develops and in small hernias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surgery versus watchful waiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful hernia repair depends upon a tension-free closure. It may be performed as an open or laparoscopic procedure and is typically achieved by placement of prosthetic mesh at the site of the defect. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inguinal hernia repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Femoral hernia repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic repair of inguinal hernias typically reduces recovery time but has a somewhat higher rate of rare complications than open repair. A decision regarding laparoscopic versus open approach will depend on local surgical expertise, and patient preferences regarding early discharge and shortened recovery time versus risk of hernia recurrence. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laparoscopic versus open repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients undergo open repair, when the above factors do not clearly favor one surgical approach (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Emergency surgery within four to six hours may prevent loss of bowel from a strangulated hernia. (See",
"      <a class=\"local\" href=\"#H2018164484\">",
"       'Strangulated hernia repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have led to conflicting results regarding the role of antibiotic prophylaxis for routine hernia surgery. We suggest not administering parenteral antibiotics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/1\">",
"      Kingsnorth A, LeBlanc K. Hernias: inguinal and incisional. Lancet 2003; 362:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/2\">",
"      McIntosh A, Hutchinson A, Roberts A, Withers H. Evidence-based management of groin hernia in primary care--a systematic review. Fam Pract 2000; 17:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/3\">",
"      Abi-Haidar Y, Sanchez V, Itani KM. Risk factors and outcomes of acute versus elective groin hernia surgery. J Am Coll Surg 2011; 213:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/4\">",
"      Gallegos NC, Dawson J, Jarvis M, Hobsley M. Risk of strangulation in groin hernias. Br J Surg 1991; 78:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/5\">",
"      Fitzgibbons RJ Jr, Giobbie-Hurder A, Gibbs JO, et al. Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA 2006; 295:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/6\">",
"      O'Dwyer PJ, Norrie J, Alani A, et al. Observation or operation for patients with an asymptomatic inguinal hernia: a randomized clinical trial. Ann Surg 2006; 244:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/7\">",
"      Leubner KD, Chop WM Jr, Ewigman B, et al. Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia? J Fam Pract 2007; 56:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/8\">",
"      Dahlstrand U, Wollert S, Nordin P, et al. Emergency femoral hernia repair: a study based on a national register. Ann Surg 2009; 249:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/9\">",
"      Cheek CM, Williams MH, Farndon JR. Trusses in the management of hernia today. Br J Surg 1995; 82:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/10\">",
"      Burns E, Whitley A. Trusses. BMJ 1990; 301:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/11\">",
"      Young DV. Comparison of local, spinal, and general anesthesia for inguinal herniorrhaphy. Am J Surg 1987; 153:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/12\">",
"      Nordin P, Zetterstr&ouml;m H, Gunnarsson U, Nilsson E. Local, regional, or general anaesthesia in groin hernia repair: multicentre randomised trial. Lancet 2003; 362:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/13\">",
"      van Veen RN, Mahabier C, Dawson I, et al. Spinal or local anesthesia in lichtenstein hernia repair: a randomized controlled trial. Ann Surg 2008; 247:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/14\">",
"      Velanovich V. Laparoscopic vs open surgery: a preliminary comparison of quality-of-life outcomes. Surg Endosc 2000; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/15\">",
"      Scott NW, McCormack K, Graham P, et al. Open mesh versus non-mesh for repair of femoral and inguinal hernia. Cochrane Database Syst Rev 2002; :CD002197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/16\">",
"      Bay-Nielsen M, Kehlet H, Strand L, et al. Quality assessment of 26,304 herniorrhaphies in Denmark: a prospective nationwide study. Lancet 2001; 358:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/17\">",
"      USHER FC. Hernia repair with Marlex mesh. An analysis of 541 cases. Arch Surg 1962; 84:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/18\">",
"      Lichtenstein IL, Shulman AG, Amid PK. The cause, prevention, and treatment of recurrent groin hernia. Surg Clin North Am 1993; 73:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/19\">",
"      Gilbert AI. An anatomic and functional classification for the diagnosis and treatment of inguinal hernia. Am J Surg 1989; 157:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/20\">",
"      Rutkow IM, Robbins AW. \"Tension-free\" inguinal herniorrhaphy: a preliminary report on the \"mesh plug\" technique. Surgery 1993; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/21\">",
"      Kugel RD. Minimally invasive, nonlaparoscopic, preperitoneal, and sutureless, inguinal herniorrhaphy. Am J Surg 1999; 178:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/22\">",
"      Simons MP, Kleijnen J, van Geldere D, et al. Role of the Shouldice technique in inguinal hernia repair: a systematic review of controlled trials and a meta-analysis. Br J Surg 1996; 83:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/23\">",
"      Shouldice, EE. The treatment of hernia. Ontario Med Rev 1953; 20:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/24\">",
"      Glassow F. The Shouldice Hospital technique. Int Surg 1986; 71:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/25\">",
"      Kingsnorth AN, Britton BJ, Morris PJ. Recurrent inguinal hernia after local anaesthetic repair. Br J Surg 1981; 68:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/26\">",
"      McKernan JB, Laws HL. Laparoscopic repair of inguinal hernias using a totally extraperitoneal prosthetic approach. Surg Endosc 1993; 7:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/27\">",
"      Ferzli G, Sayad P, Huie F, et al. Endoscopic extraperitoneal herniorrhaphy. A 5-year experience. Surg Endosc 1998; 12:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/28\">",
"      Wake BL, McCormack K, Fraser C, et al. Transabdominal pre-peritoneal (TAPP) vs totally extraperitoneal (TEP) laparoscopic techniques for inguinal hernia repair. Cochrane Database Syst Rev 2005; :CD004703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/29\">",
"      Vader VL, Vogt DM, Zucker KA, et al. Adhesion formation in laparoscopic inguinal hernia repair. Surg Endosc 1997; 11:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/30\">",
"      Kald A, Anderberg B, Carlsson P, et al. Surgical outcome and cost-minimisation-analyses of laparoscopic and open hernia repair: a randomised prospective trial with one year follow up. Eur J Surg 1997; 163:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/31\">",
"      EU Hernia Trialists Collaboration. Laparoscopic compared with open methods of groin hernia repair: systematic review of randomized controlled trials. Br J Surg 2000; 87:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/32\">",
"      Memon MA, Cooper NJ, Memon B, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic inguinal hernia repair. Br J Surg 2003; 90:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/33\">",
"      McCormack K, Scott NW, Go PM, et al. Laparoscopic techniques versus open techniques for inguinal hernia repair. Cochrane Database Syst Rev 2003; :CD001785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/34\">",
"      Medical Research Council Laparoscopic Groin Hernia Trial Group.. Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial. Br J Surg 2001; 88:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/35\">",
"      Neumayer L, Giobbie-Hurder A, Jonasson O, et al. Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med 2004; 350:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/36\">",
"      Liem MS, van der Graaf Y, van Steensel CJ, et al. Comparison of conventional anterior surgery and laparoscopic surgery for inguinal-hernia repair. N Engl J Med 1997; 336:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/37\">",
"      Jacobs DO. Mesh repair of inguinal hernias--redux. N Engl J Med 2004; 350:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/38\">",
"      Payne JH Jr, Grininger LM, Izawa MT, et al. Laparoscopic or open inguinal herniorrhaphy? A randomized prospective trial. Arch Surg 1994; 129:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/39\">",
"      Barkun JS, Keyser EJ, Wexler MJ, et al. Short-term outcomes in open vs. laparoscopic herniorrhaphy: confounding impact of worker's compensation on convalescence. J Gastrointest Surg 1999; 3:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/40\">",
"      Welsh CL, Hopton D. Advice about driving after herniorrhaphy. Br Med J 1980; 280:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/41\">",
"      Salcedo-Wasicek MC, Thirlby RC. Postoperative course after inguinal herniorrhaphy. A case-controlled comparison of patients receiving workers' compensation vs patients with commercial insurance. Arch Surg 1995; 130:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/42\">",
"      Sanchez-Manuel FJ, Seco-Gil JL. Antibiotic prophylaxis for hernia repair. Cochrane Database Syst Rev 2003; :CD003769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/43\">",
"      Sanabria A, Dom&iacute;nguez LC, Valdivieso E, G&oacute;mez G. Prophylactic antibiotics for mesh inguinal hernioplasty: a meta-analysis. Ann Surg 2007; 245:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/44\">",
"      Gilbert AI, Felton LL. Infection in inguinal hernia repair considering biomaterials and antibiotics. Surg Gynecol Obstet 1993; 177:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/45\">",
"      Bay-Nielsen M, Perkins FM, Kehlet H, Danish Hernia Database. Pain and functional impairment 1 year after inguinal herniorrhaphy: a nationwide questionnaire study. Ann Surg 2001; 233:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/46\">",
"      Condon RE. Groin pain after hernia repair. Ann Surg 2001; 233:8.",
"     </a>",
"    </li>",
"    <li>",
"     Bruce J. Postsurgical pain. In: Chronic Pain Epidemiology From Aetiology to Public Health, Croft P, Blyth FM, van der Wendt D (Eds), Oxford University Press, 2010 Oxford. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/48\">",
"      Poobalan AS, Bruce J, Smith WC, et al. A review of chronic pain after inguinal herniorrhaphy. Clin J Pain 2003; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/49\">",
"      Wright D, Paterson C, Scott N, et al. Five-year follow-up of patients undergoing laparoscopic or open groin hernia repair: a randomized controlled trial. Ann Surg 2002; 235:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/50\">",
"      Nienhuijs S, Staal E, Strobbe L, et al. Chronic pain after mesh repair of inguinal hernia: a systematic review. Am J Surg 2007; 194:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/51\">",
"      Fr&auml;nneby U, Sandblom G, Nordin P, et al. Risk factors for long-term pain after hernia surgery. Ann Surg 2006; 244:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/52\">",
"      Reinpold WM, Nehls J, Eggert A. Nerve management and chronic pain after open inguinal hernia repair: a prospective two phase study. Ann Surg 2011; 254:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29000/abstract/53\">",
"      Tverskoy M, Cozacov C, Ayache M, et al. Postoperative pain after inguinal herniorrhaphy with different types of anesthesia. Anesth Analg 1990; 70:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3687 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-8E67DEBC9C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29000=[""].join("\n");
var outline_f28_20_29000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGERY VERSUS WATCHFUL WAITING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Femoral hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2018164283\">",
"      Use of a truss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2018164484\">",
"      STRANGULATED HERNIA REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2018164221\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INGUINAL HERNIA REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Open repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laparoscopic repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laparoscopic versus open repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FEMORAL HERNIA REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECUPERATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Seromas and hematomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Persistent groin pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hernia recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11268?source=related_link\">",
"      Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26393?source=related_link\">",
"      Inguinal and femoral hernia repair: Laparoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=related_link\">",
"      Inguinal and femoral hernia repair: Open techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_20_29001="Irritant contact dermatitis in adults";
var content_f28_20_29001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Irritant contact dermatitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Ronald Goldner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Papapit Tuchinda, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29001/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/20/29001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26143600\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant contact dermatitis (ICD) is a localized inflammatory skin response to a wide range of chemical or physical agents. ICD results from direct cytotoxic effect of irritants; unlike allergic contact dermatitis (ACD) it is not immune mediated. ICD is a multifactorial disorder influenced by the physical and chemical properties of the irritating substance, host-related susceptibility factors, and environmental factors.",
"   </p>",
"   <p>",
"    The clinical manifestations of ICD are similar to those of other acute or chronic eczematous dermatitides, including atopic dermatitis and ACD.",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and management of ICD in adults. Atopic dermatitis and ACD are discussed separately. Diaper dermatitis, the prototype of irritant contact dermatitis in infants and young children, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7223?source=see_link\">",
"     \"Basic mechanisms and pathophysiology of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=see_link\">",
"     \"Management of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32782218\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant contact dermatitis (ICD) is the most common type of contact dermatitis. ICD represents approximately 80 percent of occupational contact dermatitis and is considered the most frequent cause of hand eczema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the general population, the estimated prevalence of hand eczema is about 4 percent; women are more frequently affected than men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk of occupational ICD is highest among those with \"wet work\" exposures such as food handlers, healthcare workers, mechanical industry workers, cleaners, and housekeepers (",
"    <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10852063\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mechanisms, some of which are not completely understood, are involved in the development of ICD, including [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disruption of the epidermal barrier",
"     </li>",
"     <li>",
"      Damage of cell membranes",
"     </li>",
"     <li>",
"      Cytotoxic effect on keratinocytes",
"     </li>",
"     <li>",
"      Cytokine release from keratinocytes",
"     </li>",
"     <li>",
"      Activation of innate immunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disruption of the epidermal barrier (stratum corneum) by chemical or physical irritants, resulting in increased skin permeability and transepidermal water loss (TEWL), is considered the initiating event of ICD. &nbsp;",
"   </p>",
"   <p>",
"    In experimental animal and human models, the acute disruption of the epidermal barrier from exposure to surfactants (eg, sodium lauryl sulfate) induces the release of preformed cytokines such as interleukin (IL) 1 alpha, IL-1 beta, IL-6, and tumour necrosis factor (TNF) alpha from keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. IL-1 alpha and TNF-alpha act as primary signals for the release of proinflammatory chemokines (eg, CCL20, CCL21, and CXCL8), which attract mononuclear and polymorphonuclear cells at the site of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In addition, TNF-alpha induces the expression of intercellular adhesion molecules 1 (ICAM-1) on keratinocytes, which promote the infiltration of leukocytes into the epidermis.",
"   </p>",
"   <p>",
"    Antiinflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist (IL-1RA) are also released in response to irritant exposure and may be involved in the resolution of the inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of chronic ICD is not completely understood. One hypothesis is that chronic exposure to mild irritants or wet work down-regulates the inflammatory response and stimulates cell proliferation and differentiation. A few studies have compared the cytokine levels in normal skin and in skin areas repeatedly exposed to sodium lauryl sulfate. In chronically irritated skin, the levels of IL-1 alpha and TNF-alpha were lower and the levels of IL-1 RA were higher than those measured in nonirritated skin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some individuals develop a tolerance to chronic exposure to irritants. The adaptation of the skin to repeated irritant exposures is called the hardening phenomenon. The mechanisms underlying the hardening phenomenon are unknown. Irritant-induced changes in skin morphology (eg, acanthosis and hyperkeratosis), lipid composition of the stratum corneum, barrier permeability, and expression of inflammatory mediators may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1199511\">",
"    <span class=\"h1\">",
"     PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of irritant contact dermatitis (ICD) is influenced by host-related and environmental factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1199518\">",
"    <span class=\"h2\">",
"     Host-related factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age",
"      </strong>",
"      &mdash; The skin reactivity to irritants is highest in infants and tends to decrease with age. The reactivity to irritants is lower among individuals &gt;65 years than in those &lt;30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/14\">",
"       14",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Sex",
"      </strong>",
"      &mdash; The prevalence of ICD in general and of hand dermatitis in particular is greater in women than in men. However, the higher risk in women is probably due to increased domestic and occupational exposure to detergents and &ldquo;wet work&rdquo; rather than to genuine sex differences in susceptibility [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/2\">",
"       2",
"      </a>",
"      ]. The clearance rate and prognosis are similar in men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Body site",
"      </strong>",
"      &mdash; The response to irritants varies from site to site on the body, reflecting differences in the thickness of the stratum corneum and barrier function. The face, dorsum of the hands, and finger webs are more prone to irritation from chemical substances than the palms, soles, or back [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/1,16\">",
"       1,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Atopy",
"      </strong>",
"      &mdash; Individuals with atopic dermatitis have a chronically impaired barrier function that increases their susceptibility to irritants [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In a population based study of patients with occupational skin disease, 64 percent of the subjects with ICD reported a personal or family history of atopic dermatitis or had typical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      minor signs of atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/19\">",
"       19",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic factors",
"      </strong>",
"      &mdash; Twin studies indicate that genetic factors other than atopy (eg, cytokine gene polymorphisms) may influence the susceptibility to ICD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/20\">",
"       20",
"      </a>",
"      ]. Individuals with a low threshold for the irritant effect of sodium lauryl sulfate and benzalkonium chloride have a high prevalence of a tumor necrosis factor alpha (",
"      <em>",
"       TNFA)",
"      </em>",
"      gene polymorphism that is correlated with increased TNF-alpha production [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1199526\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors such as temperature, air flow, humidity, and occlusion affect the skin response to irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High temperatures and air flow appear to decrease the skin barrier function and increase the penetration of irritants such as sodium lauryl sulfate (a surfactant contained in many detergents) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Cold temperatures and low ambient humidity increase the transepidermal water loss and the skin susceptibility to irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Increased humidity (eg, sweating from prolonged wearing of occlusive gloves) can disrupt the skin barrier and enhance the inflammatory response to chemical or mechanical irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183287\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic features of irritant contact dermatitis (ICD) vary according to the stage and severity of skin lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute ICD is characterized by mild spongiosis, intraepidermal vesicles or bullae, and necrosis of keratinocytes. A perivascular mononuclear cell infiltrate may be seen. Electron microscopy shows a condensed cytoplasm containing aggregated keratin filaments, lipid vacuoles, and membrane-bound vesicles; disrupted cell membranes; and pyknotic nuclei with condensed chromatin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic ICD is characterized by hyperkeratosis, parakeratosis, hypergranulosis, and acanthosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the histopathologic features of ICD can differentiate it from allergic contact dermatitis (ACD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link&amp;anchor=H27385290#H27385290\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143646\">",
"    <span class=\"h1\">",
"     COMMON IRRITANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritants are physical or chemical agents that are capable of producing cellular perturbation if applied to the skin for sufficient time and in sufficient concentration. Common chemical irritants include water and wet work, detergents and surfactants, solvents, oxidizing agents, acids, and alkalis. Physical irritants include metal tools, wood, fiberglass, plant parts, paper, and dust or soil. Occupations at high risk for irritant contact dermatitis and common irritants encountered are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9372529\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION OF IRRITANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of irritancy for an individual substance depends upon its chemical properties (eg, acid dissociation constant, ionization status, molecular size, or liposolubility) and the duration of the contact [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/1\">",
"     1",
"    </a>",
"    ]. High concentrations of most chemicals are sufficient to induce an irritant reaction in almost all individuals, whereas mild irritants may induce an inflammatory response only in susceptible individuals or after repeated or prolonged contact [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different chemicals may act synergistically in inducing dermatitis. Solvents remove the lipids from the stratum corneum whereas detergents remove both lipids and hygroscopic (water holding) substances (eg, filaggrin breakdown products). The combined exposure to solvents and detergents produces an additive effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10851981\">",
"    <span class=\"h2\">",
"     Chemical irritants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Water and wet work",
"      </strong>",
"      &mdash; Water is hypotonic and acts as a cytotoxic agent on eroded skin. On intact skin, prolonged contact with water causes swelling of the stratum corneum, disruption of the intercellular lipids, and enhancement of skin permeability and susceptibility to irritants [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/33\">",
"       33",
"      </a>",
"      ]. Wet work is defined as skin exposure to liquids or wearing occlusive gloves more than two hours daily or hand washing or disinfection more than 20 times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/34\">",
"       34",
"      </a>",
"      ]. Food handling and preparation, healthcare-related occupations, cleaning, and hairdressing are examples of wet work.",
"     </li>",
"     <li>",
"      <strong>",
"       Detergents and surfactants",
"      </strong>",
"      &mdash; Detergents used for domestic and industrial cleaning remove lipids and hygroscopic substances in the stratum corneum, denature proteins, and damage the cell membranes.",
"     </li>",
"     <li>",
"      <strong>",
"       Solvents",
"      </strong>",
"      &mdash; Solvents remove lipids and hygroscopic substances and damage cell membranes. Their irritating capacity depends upon their chemical structure: aromatic solvents (eg, benzene or toluene) are stronger irritants than alcohols or ketones (eg, acetone).",
"     </li>",
"     <li>",
"      <strong>",
"       Oxidizing agents",
"      </strong>",
"      &mdash; Oxidizing agents, such as sodium hypochlorite (bleach) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      are cytotoxic agents",
"     </li>",
"     <li>",
"      <strong>",
"       Acids",
"      </strong>",
"      &mdash; Strong acids (eg, sulphuric acid) cause protein coagulation and cell necrosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Alkalis",
"      </strong>",
"      &mdash; Alkaline solutions saponify the surface lipids, dissolve water-holding substances, break the cross-linkages of keratin, and cause swelling of cells. Soap, soda, ammonia, potassium and sodium hydroxides, cement, and chalk are examples of alkaline substances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143653\">",
"    <span class=\"h2\">",
"     Physical irritants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic microtrauma or friction damages the stratum corneum, impairs the skin barrier, and induces the release of preformed cytokines from keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/35\">",
"     35",
"    </a>",
"    ]. Physical agents that may cause skin irritation include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metal tools",
"     </li>",
"     <li>",
"      Wood",
"     </li>",
"     <li>",
"      Fiberglass",
"     </li>",
"     <li>",
"      Plant parts (eg, thorns, spines, sharp-edged leaves) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Paper",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Dust/soil",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical irritants may act synergistically with chemical irritants, such as detergents or water, in inducing a more severe disruption of the skin barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143730\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of irritant contact dermatitis (ICD) range from mild skin dryness and erythema to acute or chronic eczematous dermatitis and even skin necrosis (chemical burn) (",
"    <a class=\"graphic graphic_picture graphicRef71250 graphicRef61579 graphicRef59959 graphicRef50299 \" href=\"UTD.htm?33/36/34378\">",
"     picture 1A-D",
"    </a>",
"    ). The type of skin response, nature of the irritant, and exposure pattern define several clinical variants, which are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef81138 \" href=\"UTD.htm?30/13/30941\">",
"     table 2",
"    </a>",
"    ). However, acute and chronic ICD are the most common forms encountered in clinical practice.",
"   </p>",
"   <p>",
"    Acute ICD often results from a single exposure to an irritant or caustic chemical. Clinical features include erythema, edema, vesicles, bullae, and oozing (",
"    <a class=\"graphic graphic_picture graphicRef71250 graphicRef61579 \" href=\"UTD.htm?32/10/32936\">",
"     picture 1A-B",
"    </a>",
"    ). The reaction is generally limited to the site of contact and is associated with a sensation of burning, stinging, or pain. Mild cases may present with only transient erythema.",
"   </p>",
"   <p>",
"    Chronic or cumulative forms result from repeated exposures to mild irritants or low concentrations of strong irritants. Clinically, chronic ICD is characterized by erythema, scaling, lichenification, hyperkeratosis, and fissuring (",
"    <a class=\"graphic graphic_picture graphicRef59959 graphicRef50299 \" href=\"UTD.htm?13/58/14247\">",
"     picture 1C-D",
"    </a>",
"    ). Sites commonly affected are the dorsum of the hands, fingertips, and finger webs. The face may be involved in individuals exposed to volatile irritants or cosmetics.",
"   </p>",
"   <p>",
"    Chronic ICD is particularly frequent in certain categories of workers (",
"    <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"     table 1",
"    </a>",
"    ). However, host and environmental factors, such as history of atopic dermatitis and exposure to friction, dust, or temperature extremes, are contributing factors in the persistence of ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143753\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ICD is in most cases based upon the clinical finding of a localized dermatitis in a patient with a history of exposure to chemical or physical irritants (",
"    <a class=\"graphic graphic_table graphicRef56560 \" href=\"UTD.htm?3/44/3788\">",
"     table 3",
"    </a>",
"    ). Complete skin examination and accurate history taking are crucial to making the correct diagnosis.",
"   </p>",
"   <p>",
"    Patch testing is performed in most patients to exclude allergic contact dermatitis (ACD). In some cases, skin biopsy for histologic examination is necessary to exclude other skin disorders. (See",
"    <a class=\"local\" href=\"#H2787591\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bioengineering methods to assess the skin barrier function, such as the measure of transepidermal water loss (TEWL), are mainly used in experimental settings. (See",
"    <a class=\"local\" href=\"#H26143816\">",
"     'Laboratory tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2787443\">",
"    <span class=\"h2\">",
"     Skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete skin examination should be performed to evaluate the extent of the skin involvement and concomitant skin disorders. The morphology, localization, and temporal course of dermatitis often suggest the diagnosis of ICD. In most cases, the affected sites are exposed areas such as the dorsum of hands, face, and neck. However, irritants may be transferred to other skin sites by contaminated hands or clothes (eg, genitalia or intertriginous areas). Additional clinical criteria that favor the diagnosis of ICD include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of symptoms within minutes to hours of exposure",
"     </li>",
"     <li>",
"      Pain, burning, stinging, or discomfort exceeding itching",
"     </li>",
"     <li>",
"      Glazed, parched, or scalded appearance of the epidermis",
"     </li>",
"     <li>",
"      Predominance of scaling, hyperkeratosis, or fissuring over vesicular changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143767\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a patient with suspected ICD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daily activities, including occupation and hobbies",
"     </li>",
"     <li>",
"      Types of substance or machinery used at the workplace",
"     </li>",
"     <li>",
"      Workplace environment (temperature, humidity, dusts)",
"     </li>",
"     <li>",
"      Use of protective gloves or gear",
"     </li>",
"     <li>",
"      Wet work (including use of occlusive gloves)",
"     </li>",
"     <li>",
"      Hand washing habits",
"     </li>",
"     <li>",
"      Use of cleansers and skin protecting creams",
"     </li>",
"     <li>",
"      Accidental exposure",
"     </li>",
"     <li>",
"      Previous atopic dermatitis, atopic respiratory disease, or other inflammatory skin disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For occupational exposures, the material safety data sheets or the list of ingredients may be useful in identifying offending irritants (",
"    <a class=\"graphic graphic_table graphicRef55936 \" href=\"UTD.htm?15/2/15403\">",
"     table 4",
"    </a>",
"    ). In some cases, visiting the work site may be needed. Common irritants encountered in occupational settings are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143816\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patch testing",
"      </strong>",
"      &mdash; Patch testing is often necessary to exclude ACD. Standard series of allergens are usually used for initial screening. Testing for additional series or specific work site allergens may be required based upon the patient&rsquo;s exposure history. The techniques and interpretation of patch testing are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link\">",
"       \"Patch testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Histologic examination",
"      </strong>",
"      &mdash; Skin biopsy is not routinely performed for the diagnosis of ICD. However, in some cases histologic examination is useful to differentiate ICD from psoriasis or other types of inflammatory dermatoses. (See",
"      <a class=\"local\" href=\"#H183287\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Bioengineering methods",
"      </strong>",
"      &mdash; Several noninvasive techniques have been developed to measure the irritant response, including the transepidermal water loss (TEWL), erythema, and hydration of the stratum corneum [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/40\">",
"       40",
"      </a>",
"      ]. These techniques are not routinely used in clinical practice but are often employed in research settings and in the cosmetic industry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TEWL is measured by means of a device called an evaporimeter and expressed in",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       /hour.",
"      </span>",
"      Many variables influence the measurement of TEWL, including the type of evaporimeter (eg, open- or closed-chamber systems), operating conditions, age and anatomic site. The lack of a standardized method for TEWL measurement limits the clinical usefulness of the test [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The intensity of erythema can be measured by laser Doppler flowmetry, reflectance spectroscopy, or colorimetric methods [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/44-46\">",
"       44-46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hydration of the stratum corneum is evaluated by measuring its capacitance (insulating property of dry stratum corneum) or conductance (conductive property related to the water content) with a device called a corneometer [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tandem repeated irritation test",
"      </strong>",
"      &mdash; Tandem repeated irritation tests (TRIT) are based on the observation that combined mechanical irritation, detergents, and occlusion cause complementary effects on the epidermal barrier disruption [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/29\">",
"       29",
"      </a>",
"      ]. TRITs simulate real conditions in everyday life or workplaces and are used in research settings to evaluate the synergistic effect of irritants or the efficacy of barrier creams.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2787591\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common disorders that should be differentiated from irritant contact dermatitis (ICD) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergic contact dermatitis",
"      </strong>",
"      &mdash; Differentiating irritant contact dermatitis (ICD) from allergic contact dermatitis (ACD) may be challenging, because they have similar clinical and histopathologic features (",
"      <a class=\"graphic graphic_table graphicRef65351 \" href=\"UTD.htm?32/30/33260\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73185 graphicRef69623 \" href=\"UTD.htm?12/25/12698\">",
"       picture 2A-B",
"      </a>",
"      ). A positive patch test to the relevant exposure is generally diagnostic of ACD. However, the possibility of false positive (irritant) and negative patch test reactions should be evaluated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link&amp;anchor=H26564848#H26564848\">",
"       \"Patch testing\", section on 'Patch test interpretation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link&amp;anchor=H2463470#H2463470\">",
"       \"Patch testing\", section on 'Determining the clinical relevance'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link&amp;anchor=H1646554#H1646554\">",
"       \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Atopic dermatitis",
"      </strong>",
"      &mdash; History of atopic dermatitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      involvement of flexural areas suggest the diagnosis of atopic dermatitis. However, individuals with a history of atopic dermatitis are prone to the development of ICD when exposed to irritants (eg, wet works). (See",
"      <a class=\"local\" href=\"#H1199518\">",
"       'Host-related factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Psoriasis",
"      </strong>",
"      &mdash; Nonpustular palmoplantar psoriasis may be extremely difficult to differentiate from hyperkeratotic, chronic ICD (",
"      <a class=\"graphic graphic_picture graphicRef81295 graphicRef61113 \" href=\"UTD.htm?7/49/7960\">",
"       picture 3A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/48\">",
"       48",
"      </a>",
"      ]. The presence of psoriatic plaques at distant sites (eg, elbows and knees)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nail changes are clues to the correct diagnosis (",
"      <a class=\"graphic graphic_picture graphicRef70962 \" href=\"UTD.htm?15/7/15474\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hand eczema",
"      </strong>",
"      &mdash; Acute and chronic (dyshidrosiform or psoriasiform) hand eczema (",
"      <a class=\"graphic graphic_picture graphicRef55722 \" href=\"UTD.htm?42/57/43925\">",
"       picture 3C",
"      </a>",
"      ) can be difficult to differentiate from ICD. However, acute dyshidrotic eczema is characterized by vesicles and bullae on palms and soles, extending to the interdigital spaces, without involvement of the dorsal aspect of hands and feet. It occurs more frequently in adolescents and young adults, with exacerbations in the spring and summer months and spontaneous remission in fall and winter. Chronic hand eczema may have an irritant component along with an \"endogenous\" or idiopathic predisposition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of dermatitis\", section on 'Dyshidrotic eczema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fungal infection",
"      </strong>",
"      &mdash; Tinea manuum or pedis are typically unilateral or asymmetrical (",
"      <a class=\"graphic graphic_picture graphicRef57816 \" href=\"UTD.htm?9/17/9492\">",
"       picture 3D",
"      </a>",
"      ). KOH examination of scales can clarify the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H15#H15\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea pedis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Scabies",
"      </strong>",
"      &mdash; Scabies in the interdigital spaces can simulate an irritant dermatitis (",
"      <a class=\"graphic graphic_picture graphicRef64806 \" href=\"UTD.htm?37/45/38612\">",
"       picture 5",
"      </a>",
"      ). In scabies, pruritus is the dominant symptom, whereas pruritus is less common and less intense in ICD. Skin scraping, adhesive tape test, or dermoscopy can provide the correct diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link&amp;anchor=H5#H5\">",
"       \"Scabies\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link&amp;anchor=H9#H9\">",
"       \"Scabies\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143837\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5655402\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of irritant contact dermatitis (ICD) includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and avoidance of the offending irritant(s)",
"     </li>",
"     <li>",
"      Treatment of skin inflammation",
"     </li>",
"     <li>",
"      Restoration of the epidermal barrier function",
"     </li>",
"     <li>",
"      Prevention of further exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2536264\">",
"    <span class=\"h2\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of offending irritants and adoption of protective measure are critical in the management of ICD. For hand dermatitis, general measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimizing contact with detergents or other cleaning agents, polish, or solvents",
"     </li>",
"     <li>",
"      Using plastic gloves with cotton lining if wet work cannot be avoided (plastic gloves are less likely than rubber gloves to cause ACD)",
"     </li>",
"     <li>",
"      Wearing gloves in cold weather",
"     </li>",
"     <li>",
"      Using lukewarm water and small amounts of mild skin cleansers for hand washing",
"     </li>",
"     <li>",
"      Rinsing and drying hands thoroughly and gently after washing",
"     </li>",
"     <li>",
"      Using moisturizers multiple times per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In occupational settings, first line prevention strategies are based on technical and organizational hazard control. Automation of processes to reduce the need of workers to expose their skin to irritants and replacement of dangerous substances by less toxic ones are examples of primary prevention strategies.",
"   </p>",
"   <p>",
"    Individual avoidance measures may include the use of gloves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other personal protective equipment such as suits, face masks, and goggles.",
"   </p>",
"   <p>",
"    The choice of glove material depends upon the type of chemical exposure. As an example, rubber gloves provide protection from hydrosoluble substances but are inappropriate for organic solvents. Information on appropriate gloves is available from glove suppliers and may be found on the material safety data sheet, which provides important safety information about chemical compounds used in the workplace (",
"    <a class=\"graphic graphic_table graphicRef55936 \" href=\"UTD.htm?15/2/15403\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26143858\">",
"     'Gloves'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2536361\">",
"    <span class=\"h2\">",
"     Active treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active treatment of ICD is aimed at reducing the signs and symptoms of inflammation and restoring the epidermal barrier. Topical corticosteroids and emollients are used empirically. Calcineurin inhibitors are not used to treat ICD. They have not been proven effective and in some studies have been found to be irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2536281\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of ICD with topical corticosteroids depends upon the severity and location as described below. In general, ointments are preferred to creams.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For severe acute ICD or chronic ICD with conspicuous skin thickening (lichenification) not involving the face or flexural areas, we suggest a super high potency (group one (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) topical corticosteroid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate). Topical corticosteroids are applied once or twice daily for two to four weeks.",
"     </li>",
"     <li>",
"      For milder forms of ICD not involving the face or flexural areas, we suggest high potency (groups two and three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) corticosteroids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"       fluocinonide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      dipropionate). Topical corticosteroids are applied once or twice daily for two to four weeks.",
"     </li>",
"     <li>",
"      For acute or chronic ICD involving the face or flexural areas, we suggest medium or low-potency (groups five and six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) topical corticosteroids. Topical corticosteroids are applied once or twice daily for one to two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of topical corticosteroids in the treatment of ICD has not been evaluated in randomized trials and their use remains controversial. A few small observational studies of experimentally induced ICD could not demonstrate the efficacy of topical corticosteroids in restoring the epidermal barrier function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In one study, ICD was induced in 36 healthy volunteers with sodium lauryl sulfate and nonanoic acid.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate, glycerol, vehicle, and no treatment were applied by each participant on separate sites of irritated skin. After 10 days, the treated and untreated sites showed a similar improvement in irritation, evaluated by a visual assessment score and measurement of transepidermal water loss (TEWL) and stratum corneum hydration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of proven benefit in clinical trials, topical corticosteroids are used in clinical practice because of their antiinflammatory properties and their efficacy in other forms of eczematous dermatitis. These potential benefits must be weighed against the adverse effects of topical corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H758405\">",
"    <span class=\"h3\">",
"     Emollients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emollients or moisturizers are beneficial in all patients with ICD. They soften the stratum corneum, reduce the transepidermal water loss, and attract water to the stratum corneum (",
"    <a class=\"graphic graphic_table graphicRef72872 \" href=\"UTD.htm?8/31/8700\">",
"     table 7",
"    </a>",
"    ). Emollients and moisturizers are used to decrease irritation and improve or restore the skin barrier function in ICD. Because they are effective only when present on the skin, emollients and moisturizers should be liberally applied multiple times per day, particularly after hand washing, and after work. &nbsp;",
"   </p>",
"   <p>",
"    Occlusive emollients (eg, petrolatum, lanolin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    , vegetable oils, beeswax, ceramides, and silicones) retard the transepidermal water loss; humectants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , propylene glycol, or urea) are hygroscopic substances with a high capacity to attract water to the stratum corneum from the atmosphere and from the deeper epidermis and dermis. They are combined with occlusive emollients in many commercially available products (sample brand names Aveeno&reg; Moisturizing Cream, Cetaphil&reg; Cream, Eucerin&reg; Original). Petrolatum-based products are preferred to emollients containing lanolin or fragrances to reduce the risk of contact sensitization. Petrolatum-based products are widely available and inexpensive.",
"   </p>",
"   <p>",
"    The efficacy of moisturizers has been evaluated in several studies of experimentally induced skin irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/52\">",
"     52",
"    </a>",
"    ]. In one representative study, six different lipid-rich moisturizers were effective in reducing erythema, scaling, and transepidermal water loss in skin irritated by sodium lauryl sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/53\">",
"     53",
"    </a>",
"    ]. This study did not find a difference between moisturizers containing physiologic lipids (eg, cholesterol, ceramide, oleic acid, or palmitic acid) and those containing nonphysiologic lipids, such as petrolatum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2536293\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gloves and barrier creams combined with adequate skin care are widely recommended as the most important measures of personal protection in occupations at increased risk of ICD. The use of personal protective equipment such as suits, face masks, and goggles also may be beneficial in preventing exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143858\">",
"    <span class=\"h3\">",
"     Gloves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate protection from contact with irritants is a key measure to prevent ICD. Since the hands are most frequently exposed to irritants in workplaces and households, the use of appropriate gloves is generally recommended to prevent ICD. The patient should be instructed to use gloves in connection with wet or dirty work at the workplace or at home. Tight-fitting gloves should be used as long as necessary, but for the shortest time possible to limit sweating and maceration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/54\">",
"     54",
"    </a>",
"    ]. Thin cotton gloves should be worn under tight-fitting gloves and changed as soon as they become damp.",
"   </p>",
"   <p>",
"    The efficacy of gloves in preventing ICD in the workplace has not been evaluated in clinical trials. Guidelines and recommendations on glove use are generally based upon local rules and regulations or clinical experience.",
"   </p>",
"   <p>",
"    Manufacturers of protective gloves provide lists of applications, hazards, and chemicals for which their gloves have been tested (eg, www.bestglove.com or www.ansell.com). &nbsp;Additional information can be obtained from the material safety data sheet, which provides important safety information about chemical compounds used in the workplace (",
"    <a class=\"graphic graphic_table graphicRef55936 \" href=\"UTD.htm?15/2/15403\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For optimal protection, the gloves must be used, maintained, and replaced according to the manufacturer&rsquo;s instructions. Failure to provide protection may be due to [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wrong glove material",
"     </li>",
"     <li>",
"      Misuse (eg, contamination of the glove interior from incorrect wearing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      removal)",
"     </li>",
"     <li>",
"      Physical damage",
"     </li>",
"     <li>",
"      Degradation",
"     </li>",
"     <li>",
"      Permeation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143865\">",
"    <span class=\"h3\">",
"     Barrier creams",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent ICD of the hands, we suggest the application of barrier creams or emollients before exposure and multiple times per day if exposure continues. (See",
"    <a class=\"local\" href=\"#H758405\">",
"     'Emollients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Barrier creams are designed to reduce the penetration of hazardous materials into the skin. Some are specifically formulated for individual chemical exposures. In general, barrier creams contain silicones (eg, dimethicone), liquid paraffin, aluminum chlorohydrate, or other water repellant compounds, such as perfluoropolyethers (sample brand names Barriere&trade; Cream, Cetaphil&reg; Barriere Cream, Excipial protect&trade;, Arretil&trade;).",
"   </p>",
"   <p>",
"    A systematic review of four clinical trials performed in occupational settings concluded that the use of barrier creams and moisturizers by metalworkers, print and dye industry workers, and hairdressers may help in preventing hand ICD in these occupations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the individual studies were small and had methodologic limitations.",
"   </p>",
"   <p>",
"    A subsequent randomized trial simulating the exposure to handwashing of health care workers, found that the regular application of moisturizers after repeated hand washing (15 times per day), prevents the development of ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barrier creams are generally well tolerated. Side effects are mild and include transient itching, stinging, and dryness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26143879\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of acute irritant contact dermatitis (ICD) is generally good if the offending irritant is removed and preventive measures are adopted. The recovery of the barrier function after acute ICD is achieved approximately four weeks after irritant exposure, whereas skin hyperreactivity in the affected areas may persist for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of chronic ICD is variable. In a one-year follow-up study of patients with occupational ICD, 43 percent reported improvement, 26 percent persistent dermatitis, and 11 percent aggravation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/60\">",
"     60",
"    </a>",
"    ]. History of atopic dermatitis was the most important determinant of persistence or aggravation.",
"   </p>",
"   <p>",
"    In a long-term study of occupational hand eczema, healing occurred in 35 percent of patients 7 to 14 years after the initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29001/abstract/61\">",
"     61",
"    </a>",
"    ]. Negative prognostic factors were history of respiratory or skin atopy, disease duration, food-related occupation, and maintaining the same occupation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20859398\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritant contact dermatitis (ICD) is a localized inflammatory skin response to exposure to a wide range of chemical or physical agents. ICD is the most common type of occupational dermatitis, particularly among food handlers, healthcare workers, mechanical industry workers, cleaners, and housekeepers (",
"      <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"       table 1",
"      </a>",
"      ). The most important predisposing factor for ICD is a history of atopic dermatitis. (See",
"      <a class=\"local\" href=\"#H26143600\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32782218\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1199511\">",
"       'Predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms involved in the development of ICD include the disruption of the epidermal barrier, damage of keratinocytes, release of inflammatory cytokines, and activation of innate immunity. (See",
"      <a class=\"local\" href=\"#H10852063\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common chemical irritants include water and wet work, detergents and surfactants, solvents, oxidizing agents, acids, and alkalis. Physical irritants include metal tools, wood, fiberglass, plant parts, paper, and dust or soil (",
"      <a class=\"graphic graphic_table graphicRef56218 \" href=\"UTD.htm?13/4/13389\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10851981\">",
"       'Chemical irritants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26143653\">",
"       'Physical irritants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute and chronic ICD are the most common clinical variants (",
"      <a class=\"graphic graphic_table graphicRef81138 \" href=\"UTD.htm?30/13/30941\">",
"       table 2",
"      </a>",
"      ). Clinical features of acute ICD include erythema, edema, formation of vesicles and bullae, and oozing (",
"      <a class=\"graphic graphic_picture graphicRef71250 graphicRef61579 \" href=\"UTD.htm?32/10/32936\">",
"       picture 1A-B",
"      </a>",
"      ). In chronic ICD, lichenification, hyperkeratosis, and fissuring are usually seen. Sites commonly affected are the dorsum of the hands, fingertips, and finger webs (",
"      <a class=\"graphic graphic_picture graphicRef59959 graphicRef50299 \" href=\"UTD.htm?13/58/14247\">",
"       picture 1C-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26143730\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, the diagnosis of ICD is based upon the clinical finding of a localized dermatitis in a patient with a history of exposure to chemical or physical irritants (",
"      <a class=\"graphic graphic_table graphicRef56560 \" href=\"UTD.htm?3/44/3788\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71250 graphicRef61579 \" href=\"UTD.htm?32/10/32936\">",
"       picture 1A-B",
"      </a>",
"      ). Patch testing may be necessary to exclude allergic contact dermatitis. (See",
"      <a class=\"local\" href=\"#H26143753\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common disorders that should be differentiated from ICD include allergic contact dermatitis, atopic dermatitis, psoriasis, endogenous eczema, and fungal infection (",
"      <a class=\"graphic graphic_picture graphicRef81295 graphicRef61113 graphicRef55722 graphicRef57816 graphicRef69623 \" href=\"UTD.htm?41/55/42874\">",
"       picture 2B, 3A-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2787591\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of ICD includes the identification and avoidance of the offending irritant(s), treatment of skin inflammation, restoration of the epidermal barrier, and prevention of further exposure. (See",
"      <a class=\"local\" href=\"#H5655402\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2536264\">",
"       'Avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest topical corticosteroids for the treatment of ICD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For severe acute ICD or chronic ICD with conspicuous skin thickening (lichenification) not involving the face or flexural areas, we generally use a super high potency (group one (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) topical corticosteroid. Topical corticosteroids are applied once or twice daily for two to four weeks.",
"     </li>",
"     <li>",
"      For milder forms of ICD not involving the face or flexural areas, we generally use high potency (groups two and three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) corticosteroids. Topical corticosteroids are applied once or twice daily for two to four weeks.",
"     </li>",
"     <li>",
"      For acute or chronic ICD involving the face or flexural areas, we generally use medium or low-potency (groups five and six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 6",
"      </a>",
"      )) topical corticosteroids. Topical corticosteroids are applied once or twice daily for one to two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest emollients and moisturizers for patients with acute or chronic ICD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Petrolatum-based products are widely available and inexpensive. Emollients are liberally applied to the affected skin multiple times per day, particularly after hand washing, and after work. (See",
"      <a class=\"local\" href=\"#H758405\">",
"       'Emollients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention measures for ICD include the use of appropriate gloves, barrier creams, and emollients. Glove manufacturers provide lists of applications, hazards, and chemicals for which their gloves have been tested. We suggest the use of barrier creams and emollients rather than gloves alone for the prevention of ICD in individuals exposed to wet work or other chemical or physical irritants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Barrier creams and emollients are applied before work and multiple times per day if the exposure continues. (See",
"      <a class=\"local\" href=\"#H26143858\">",
"       'Gloves'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26143865\">",
"       'Barrier creams'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/1\">",
"      Clark SC, Zirwas MJ. Management of occupational dermatitis. Dermatol Clin 2009; 27:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/2\">",
"      Thyssen JP, Johansen JD, Linneberg A, Menn&eacute; T. The epidemiology of hand eczema in the general population--prevalence and main findings. Contact Dermatitis 2010; 62:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/3\">",
"      Dickel H, Kuss O, Schmidt A, et al. Importance of irritant contact dermatitis in occupational skin disease. Am J Clin Dermatol 2002; 3:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/4\">",
"      Smith HR, Basketter DA, McFadden JP. Irritant dermatitis, irritancy and its role in allergic contact dermatitis. Clin Exp Dermatol 2002; 27:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/5\">",
"      Fluhr JW, Darlenski R, Angelova-Fischer I, et al. Skin irritation and sensitization: mechanisms and new approaches for risk assessment. 1. Skin irritation. Skin Pharmacol Physiol 2008; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/6\">",
"      Wood LC, Elias PM, Calhoun C, et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol 1996; 106:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/7\">",
"      Wilmer JL, Burleson FG, Kayama F, et al. Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin. J Invest Dermatol 1994; 102:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/8\">",
"      Spiekstra SW, Toebak MJ, Sampat-Sardjoepersad S, et al. Induction of cytokine (interleukin-1alpha and tumor necrosis factor-alpha) and chemokine (CCL20, CCL27, and CXCL8) alarm signals after allergen and irritant exposure. Exp Dermatol 2005; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/9\">",
"      Eberhard Y, Ortiz S, Ruiz Lascano A, et al. Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants. BMC Immunol 2004; 5:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/10\">",
"      De Jongh CM, Verberk MM, Withagen CE, et al. Stratum corneum cytokines and skin irritation response to sodium lauryl sulfate. Contact Dermatitis 2006; 54:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/11\">",
"      Visscher MO, Said D, Wickett R. Stratum corneum cytokines, structural proteins, and transepidermal water loss: effect of hand hygiene. Skin Res Technol 2010; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/12\">",
"      Heinemann C, Paschold C, Fluhr J, et al. Induction of a hardening phenomenon by repeated application of SLS: analysis of lipid changes in the stratum corneum. Acta Derm Venereol 2005; 85:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/13\">",
"      Watkins SA, Maibach HI. The hardening phenomenon in irritant contact dermatitis: an interpretative update. Contact Dermatitis 2009; 60:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/14\">",
"      Schwindt DA, Wilhelm KP, Miller DL, Maibach HI. Cumulative irritation in older and younger skin: a comparison. Acta Derm Venereol 1998; 78:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/15\">",
"      Goh CL. Prognosis of contact and occupational dermatitis. Clin Dermatol 1997; 15:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/16\">",
"      Rougier A, Dupuis D, Lotte C, et al. Regional variation in percutaneous absorption in man: measurement by the stripping method. Arch Dermatol Res 1986; 278:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/17\">",
"      Jakasa I, de Jongh CM, Verberk MM, et al. Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br J Dermatol 2006; 155:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/18\">",
"      Jakasa I, Verberk MM, Esposito M, et al. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 2007; 127:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/19\">",
"      Dickel H, Bruckner TM, Schmidt A, Diepgen TL. Impact of atopic skin diathesis on occupational skin disease incidence in a working population. J Invest Dermatol 2003; 121:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/20\">",
"      Lerbaek A, Kyvik KO, Mortensen J, et al. Heritability of hand eczema is not explained by comorbidity with atopic dermatitis. J Invest Dermatol 2007; 127:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/21\">",
"      de Jongh CM, John SM, Bruynzeel DP, et al. Cytokine gene polymorphisms and susceptibility to chronic irritant contact dermatitis. Contact Dermatitis 2008; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/22\">",
"      Allen MH, Wakelin SH, Holloway D, et al. Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis. Immunogenetics 2000; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/23\">",
"      Zhai H, Maibach HI. Skin occlusion and irritant and allergic contact dermatitis: an overview. Contact Dermatitis 2001; 44:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/24\">",
"      Ohlenschlaeger J, Friberg J, Ramsing D, Agner T. Temperature dependency of skin susceptibility to water and detergents. Acta Derm Venereol 1996; 76:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/25\">",
"      Berardesca E, Vignoli GP, Distante F, et al. Effects of water temperature on surfactant-induced skin irritation. Contact Dermatitis 1995; 32:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/26\">",
"      Fluhr JW, Praessler J, Akengin A, et al. Air flow at different temperatures increases sodium lauryl sulphate-induced barrier disruption and irritation in vivo. Br J Dermatol 2005; 152:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/27\">",
"      John SM, Uter W. Meteorological influence on NaOH irritation varies with body site. Arch Dermatol Res 2005; 296:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/28\">",
"      Uter W, Gefeller O, Schwanitz HJ. An epidemiological study of the influence of season (cold and dry air) on the occurrence of irritant skin changes of the hands. Br J Dermatol 1998; 138:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/29\">",
"      Fluhr JW, Akengin A, Bornkessel A, et al. Additive impairment of the barrier function by mechanical irritation, occlusion and sodium lauryl sulphate in vivo. Br J Dermatol 2005; 153:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/30\">",
"      Willis CM, Stephens CJ, Wilkinson JD. Epidermal damage induced by irritants in man: a light and electron microscopic study. J Invest Dermatol 1989; 93:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/31\">",
"      Aramaki J, L&ouml;ffler C, Kawana S, et al. Irritant patch testing with sodium lauryl sulphate: interrelation between concentration and exposure time. Br J Dermatol 2001; 145:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/32\">",
"      Wigger-Alberti W, Krebs A, Elsner P. Experimental irritant contact dermatitis due to cumulative epicutaneous exposure to sodium lauryl sulphate and toluene: single and concurrent application. Br J Dermatol 2000; 143:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/33\">",
"      Warner RR, Boissy YL, Lilly NA, et al. Water disrupts stratum corneum lipid lamellae: damage is similar to surfactants. J Invest Dermatol 1999; 113:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/34\">",
"      Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health 1999; 72:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/35\">",
"      Pigatto PD, Legori A, Bigardi AS. Occupational dermatitis from physical causes. Clin Dermatol 1992; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/36\">",
"      Bordel-G&oacute;mez MT, Miranda-Romero A. Fibreglass dermatitis: a report of 2 cases. Contact Dermatitis 2008; 59:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/37\">",
"      Modi GM, Doherty CB, Katta R, Orengo IF. Irritant contact dermatitis from plants. Dermatitis 2009; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/38\">",
"      Morris-Jones R, Robertson SJ, Ross JS, et al. Dermatitis caused by physical irritants. Br J Dermatol 2002; 147:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/39\">",
"      Rietschel RL. Clues to an accurate diagnosis of contact dermatitis. Dermatol Ther 2004; 17:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/40\">",
"      K&uuml;tting B, Uter W, Baumeister T, et al. Non-invasive bioengineering methods in an intervention study in 1020 male metal workers: results and implications for occupational dermatology. Contact Dermatitis 2010; 62:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/41\">",
"      Steiner M, Aikman-Green S, Prescott GJ, Dick FD. Side-by-side comparison of an open-chamber (TM 300) and a closed-chamber (Vapometer(&trade;) ) transepidermal water loss meter. Skin Res Technol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/42\">",
"      Elkeeb R, Hui X, Chan H, et al. Correlation of transepidermal water loss with skin barrier properties in vitro: comparison of three evaporimeters. Skin Res Technol 2010; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/43\">",
"      Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1990; 22:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/44\">",
"      Bircher A, de Boer EM, Agner T, et al. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1994; 30:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/45\">",
"      Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter(R), the DermaSpectrometer(R) and the Mexameter(R). Skin Res Technol 2000; 6:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/46\">",
"      Andersen PH, Maibach HI. Skin irritation in man: a comparative bioengineering study using improved reflectance spectroscopy. Contact Dermatitis 1995; 33:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/47\">",
"      Clarys P, Clijsen R, Taeymans J, Barel AO. Hydration measurements of the stratum corneum: comparison between the capacitance method (digital version of the Corneometer CM 825&reg;) and the impedance method (Skicon-200EX&reg;). Skin Res Technol 2012; 18:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/48\">",
"      Aydin O, Engin B, Ouz O, et al. Non-pustular palmoplantar psoriasis: is histologic differentiation from eczematous dermatitis possible? J Cutan Pathol 2008; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/49\">",
"      Clemmensen A, Andersen F, Petersen TK, et al. Applicability of an exaggerated forearm wash test for efficacy testing of two corticosteroids, tacrolimus and glycerol, in topical formulations against skin irritation induced by two different irritants. Skin Res Technol 2011; 17:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/50\">",
"      Levin C, Zhai H, Bashir S, et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis? Skin Res Technol 2001; 7:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/51\">",
"      Le TK, De Mon P, Schalkwijk J, van der Valk PG. Effect of a topical corticosteroid, a retinoid and a vitamin D3 derivative on sodium dodecyl sulphate induced skin irritation. Contact Dermatitis 1997; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/52\">",
"      Yokota M, Maibach HI. Moisturizer effect on irritant dermatitis: an overview. Contact Dermatitis 2006; 55:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/53\">",
"      Held E, Lund H, Agner T. Effect of different moisturizers on SLS-irritated human skin. Contact Dermatitis 2001; 44:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/54\">",
"      Menn&eacute; T, Johansen JD, Sommerlund M, et al. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis 2011; 65:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/55\">",
"      Packham C. Gloves as chemical protection--can they really work? Ann Occup Hyg 2006; 50:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/56\">",
"      Bauer A, Schmitt J, Bennett C, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2010; :CD004414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/57\">",
"      Williams C, Wilkinson SM, McShane P, et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol 2010; 162:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/58\">",
"      Lee JY, Effendy I, Maibach HI. Acute irritant contact dermatitis: recovery time in man. Contact Dermatitis 1997; 36:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/59\">",
"      Choi JM, Lee JY, Cho BK. Chronic irritant contact dermatitis: recovery time in man. Contact Dermatitis 2000; 42:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/60\">",
"      Cvetkovski RS, Zachariae R, Jensen H, et al. Prognosis of occupational hand eczema: a follow-up study. Arch Dermatol 2006; 142:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29001/abstract/61\">",
"      M&auml;lk&ouml;nen T, Alanko K, Jolanki R, et al. Long-term follow-up study of occupational hand eczema. Br J Dermatol 2010; 163:999.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13661 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29001=[""].join("\n");
var outline_f28_20_29001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20859398\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143600\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32782218\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10852063\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1199511\">",
"      PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1199518\">",
"      Host-related factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1199526\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183287\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143646\">",
"      COMMON IRRITANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9372529\">",
"      MECHANISM OF ACTION OF IRRITANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10851981\">",
"      Chemical irritants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26143653\">",
"      Physical irritants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143730\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143753\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2787443\">",
"      Skin examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26143767\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26143816\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2787591\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143837\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5655402\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2536264\">",
"      Avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2536361\">",
"      Active treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2536281\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H758405\">",
"      - Emollients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2536293\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26143858\">",
"      - Gloves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26143865\">",
"      - Barrier creams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26143879\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20859398\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13661|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/11/5300\" title=\"picture 1A\">",
"      Irritant contact dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/41/18067\" title=\"picture 1B\">",
"      Irritant contact dermatitis acute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/12/37061\" title=\"picture 1C\">",
"      Chronic irritant contact dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/17/28958\" title=\"picture 1D\">",
"      Chronic irritant contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/24/41351\" title=\"picture 2A\">",
"      Contact dermatitis impetiginized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/17/3348\" title=\"picture 2B\">",
"      Contact dermatitis chronic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/15/17652\" title=\"picture 3A\">",
"      Psoriasis palmar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/3/28721\" title=\"picture 3B\">",
"      Psoriasis palmar 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/57/43925\" title=\"picture 3C\">",
"      Dyshidrotic eczema hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/17/9492\" title=\"picture 3D\">",
"      Tinea pedis manuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/7/15474\" title=\"picture 4\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/45/38612\" title=\"picture 5\">",
"      Scabies interdigital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/4/13389\" title=\"table 1\">",
"      Occupational exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/13/30941\" title=\"table 2\">",
"      Irritant contact dermatitis clinical classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/44/3788\" title=\"table 3\">",
"      Irritant contact dermatitis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/2/15403\" title=\"table 4\">",
"      Material safety data sheet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/30/33260\" title=\"table 5\">",
"      Irritant and allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 6\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/31/8700\" title=\"table 7\">",
"      Types of moisturizers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7223?source=related_link\">",
"      Basic mechanisms and pathophysiology of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=related_link\">",
"      Management of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=related_link\">",
"      Patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_20_29002="Treatment and outcome of nausea and vomiting of pregnancy";
var content_f28_20_29002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and outcome of nausea and vomiting of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Judith A Smith, Pharm D, BCOP, CPHQ, FCCP, FISOPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Jerrie S Refuerzo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/20/29002/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/20/29002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea with or without vomiting is common in early pregnancy. Severe vomiting resulting in dehydration and weight loss is termed hyperemesis gravidarum and occurs infrequently. Symptoms usually resolve by midpregnancy regardless of severity and therapy.",
"   </p>",
"   <p>",
"    Management of affected women depends upon the impact of her symptoms on her health and quality of life, and the safety of maternal treatment for the fetus. Treatment approaches include",
"    <span class=\"nowrap\">",
"     dietary/lifestyle",
"    </span>",
"    changes, oral or rectal medication, and hospitalization for parenteral fluids and therapies in women who fail to respond to outpatient management and continue to lose weight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/1\">",
"     1",
"    </a>",
"    ]. Enteral or parenteral nutrition may be required.",
"   </p>",
"   <p>",
"    The treatment of nausea and vomiting of pregnancy will be reviewed here. The clinical features and evaluation of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169438327\">",
"    <span class=\"h1\">",
"     GOAL OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment goals in patients with nausea and vomiting of pregnancy are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce symptoms through changes in",
"      <span class=\"nowrap\">",
"       diet/environment",
"      </span>",
"      and by medication",
"     </li>",
"     <li>",
"      Correct consequences or complications of nausea and vomiting (eg, fluid depletion, hypokalemia, and metabolic alkalosis)",
"     </li>",
"     <li>",
"      Minimize the fetal effects of maternal nausea and vomiting and their treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389041\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, treatment begins with advice about diet, avoidance of triggers, and non-pharmacologic interventions, such as acupressure; oral or rectal medications are added if symptoms do not improve (",
"    <a class=\"graphic graphic_algorithm graphicRef74451 \" href=\"UTD.htm?7/48/7941\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389346\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meals and snacks should be eaten slowly and in small amounts every one to two hours to avoid a full stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/2\">",
"     2",
"    </a>",
"    ]. Women with nausea should eat before, or as soon as, they feel hungry to avoid an empty stomach, which can aggravate nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/3\">",
"     3",
"    </a>",
"    ]. A snack before getting out of bed in the morning can be helpful.",
"   </p>",
"   <p>",
"    Clinicians commonly recommend ingestion of frequent small carbohydrate meals, such as soda crackers or dry toast, based primarily on historical anecdotal reports [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/4\">",
"     4",
"    </a>",
"    ]. Although scientific data on the effect of dietary components on nausea are sparse, there is some evidence that protein-predominant",
"    <span class=\"nowrap\">",
"     meals/snacks",
"    </span>",
"    produce quantifiable decreases in nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Woman should figure out what foods they tolerate best and try to eat those foods. Dietary manipulations that help some women include eliminating coffee and spicy, odorous, high fat, acidic, and very sweet foods, and substituting",
"    <span class=\"nowrap\">",
"     snacks/meals",
"    </span>",
"    that are protein dominant, salty, low fat, bland,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dry (eg, nuts, pretzels, crackers, cereal, toast) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluids are better tolerated if cold, clear, and carbonated or sour (eg, ginger ale, lemonade, popsicles), and if taken in small amounts between meals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/7\">",
"     7",
"    </a>",
"    ]. Liquids can be taken in small amounts with a straw. Small volumes of electrolyte-replacement sports drinks replace both fluids and electrolytes. Aromatic therapies involving lemon (lemonade), mint (tea), or orange have also been described as useful. Fluids should be consumed at least 30 minutes before or after solid food to minimize the effect of a full stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients whose symptoms are related to delayed gastric emptying should improve with a diet comprised of liquids and low fat solids since these foods are more readily emptied by the stomach; however, it is not known to what degree gastric emptying and dysfunction account for symptoms in women with nausea and vomiting of pregnancy.",
"   </p>",
"   <p>",
"    Drinking peppermint tea or sucking peppermint candies can reduce postprandial nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Avoidance of triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of nonpharmacologic therapy of hyperemesis gravidarum is avoidance of environmental triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/6\">",
"     6",
"    </a>",
"    ]. Examples of some triggers include: stuffy rooms, odors (eg, perfume, chemicals, food, smoke) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/9\">",
"     9",
"    </a>",
"    ], heat, humidity, noise, and visual or physical motion (eg, flickering lights, driving) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/10\">",
"     10",
"    </a>",
"    ]. Quickly changing position and not getting enough rest, particularly after eating, may also aggravate symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/11\">",
"     11",
"    </a>",
"    ]. Lying down soon after eating and lying on the left side are additional potentially aggravating factors because these actions may delay gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/2\">",
"     2",
"    </a>",
"    ]. Cold solid foods are tolerated better than hot solid foods because they have less odor and require less preparation time (ie, shorter exposure to the trigger if the woman is preparing her own meal) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/2\">",
"     2",
"    </a>",
"    ]. Brushing teeth after a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/8\">",
"     8",
"    </a>",
"    ], spitting out saliva, and frequently washing out the mouth can be helpful.",
"   </p>",
"   <p>",
"    Supplements containing iron should be avoided until symptoms resolve, as iron causes gastric irritation and can provoke nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/12\">",
"     12",
"    </a>",
"    ]. Taking prenatal vitamins before bed with a snack, instead of in the morning or on an empty stomach, may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acupuncture and acupressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;P6 acupressure wristbands (",
"    <a class=\"graphic graphic_picture graphicRef82211 \" href=\"UTD.htm?21/28/21956\">",
"     picture 1",
"    </a>",
"    ) do not require a prescription and have become a popular self-administered intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/14\">",
"     14",
"    </a>",
"    ]. A Cochrane review of randomized trials did not find P6 acupuncture or acupressure wristbands significantly more effective than sham therapy, although some individual trials showed a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15\">",
"     15",
"    </a>",
"    ]. One reason may be that a strong placebo effect has been observed in patients who receive sham therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Self-administered nerve stimulation therapy over the volar aspect of the wrist at the P6 acupressure point using a commercial device also showed some promise in a randomized, controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/20\">",
"     20",
"    </a>",
"    ]. P6 acupuncture or acupressure has not been associated with any adverse effects on pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnosis has been reported to be helpful in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/21\">",
"     21",
"    </a>",
"    ]. Psychotherapy can also be a useful adjunctive therapy, particularly if psychological sources of anxiety are identified and can be ameliorated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, pregnant women have been excluded from most clinical drug trials. Thus, there are limited data from pregnant women to support the safety and efficacy of agents used to treat nausea and vomiting. A number of reports have demonstrated that antiemetic drug therapy is more effective than placebo and does not increase the incidence of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/24\">",
"     24",
"    </a>",
"    ]. However, there is little evidence from well-designed comparative trials upon which to base a treatment plan for women with nausea and vomiting of pregnancy.",
"   </p>",
"   <p>",
"    If non-pharmacologic interventions fail, a reasonable approach is to consider the addition of pharmacotherapy with drugs that are reported to be effective and have the best maternal-fetal safety profile. If the initial drug is ineffective, then other drugs are added in a step-wise progression (",
"    <a class=\"graphic graphic_algorithm graphicRef74451 \" href=\"UTD.htm?7/48/7941\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/1,25,26\">",
"     1,25,26",
"    </a>",
"    ]. We typically continue a patient on a drug for several days to determine whether her nausea and vomiting are improving. If her symptoms persist, then we add another drug to the existing regimen; however, if she is experiencing side effects, then we substitute another drug in its place.",
"   </p>",
"   <p>",
"    These patients require frequent assessment of their medical status and response to therapy; women with mild to moderate nausea and vomiting of pregnancy are evaluated daily, whereas those with severe disease are evaluated from hour to hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Complementary and alternative medications (CAM)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Ginger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and controlled studies suggest that powdered ginger (1 to 1.5 grams in divided doses over 24 hours) is more effective than placebo, and equivalent to vitamin B6 (pyridoxine) for treatment of nausea and vomiting of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. A meta-analysis has not been performed because the trials used different control groups and measures to assess outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/31\">",
"     31",
"    </a>",
"    ]. No increased risk of adverse effects on pregnancy outcome has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/32\">",
"     32",
"    </a>",
"    ], but larger studies are needed to establish the safety and efficacy of ginger.",
"   </p>",
"   <p>",
"    We suggest use of ginger containing foods (eg, ginger lollipops, ginger tea) or ginger supplements (eg, 250 mg capsules orally four times a day) for mild nausea and vomiting. Standard pharmacologic-grade ginger preparations are not readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/33\">",
"     33",
"    </a>",
"    ]; we do not prescribe powdered ginger.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most CAM approaches have not been studied rigorously for efficacy or safety, and should be avoided for this reason. As an example, in 2009, the FDA notified healthcare professionals and pregnant or breastfeeding women to avoid consuming Nzu, a traditional African remedy for morning sickness, because of potential health risks from high levels of lead and arsenic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/34\">",
"     34",
"    </a>",
"    ]. Nzu may be sold under such names as Calabash clay, Calabar stone, Mabele, Argile, or La Craie.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pyridoxine (vitamin B6)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine is a water-soluble B-complex vitamin that is a necessary coenzyme in the metabolism of lipids, carbohydrates, and amino acids. It can be used as a single agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/35\">",
"     35",
"    </a>",
"    ] or in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    succinate for the treatment of nausea of pregnancy (see",
"    <a class=\"local\" href=\"#H217701\">",
"     'Doxylamine succinate and pyridoxine'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of randomized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    controlled trials have shown that pyridoxine (vitamin B6) improves mild to moderate nausea, but does not significantly reduce vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15,27,36\">",
"     15,27,36",
"    </a>",
"    ]. Thus, it is most useful for women with mild disease rather than hyperemesis. The mechanism for the therapeutic effect of pyridoxine in women with nausea is unknown. Hypotheses to explain the beneficial effects of pyridoxine include",
"    <span class=\"nowrap\">",
"     prevention/treatment",
"    </span>",
"    of vitamin B6 deficiency, intrinsic antinausea properties,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    synergy with the antinausea properties of antihistamines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/37\">",
"     37",
"    </a>",
"    ]. Although vitamin B6 levels decrease as gestation advances, there is no proven correlation between maternal vitamin B6 levels and incidence or severity of nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a single agent, the initial dose of pyridoxine is 25 mg orally every six to eight hours; the maximum dose suggested for pregnant women is 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but cumulative doses up to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    appear to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/39\">",
"     39",
"    </a>",
"    ]. Pyridoxine has a good safety profile with minimal side effects and is easy to obtain; therefore, it is a reasonable first-line treatment for nausea and vomiting of pregnancy, either alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    succinate. Where available, we suggest pyridoxine-doxylamine succinate combination therapy for initial pharmacologic treatment of nausea of pregnancy (see",
"    <a class=\"local\" href=\"#H217701\">",
"     'Doxylamine succinate and pyridoxine'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antihistamines (H1 antagonists)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few antihistamines have been studied for the treatment of nausea and vomiting of pregnancy. The most commonly used antihistamine is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    in combination with pyridoxine. Other antihistamines that have been used independently to treat nausea and vomiting of pregnancy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    . There are no data on use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    patch for nausea and vomiting of pregnancy.",
"   </p>",
"   <p>",
"    The efficacy of antihistamines was illustrated in an analysis of pooled data from controlled trials that found use of these agents significantly reduced pregnancy-related nausea and vomiting (RR 0.34, 95% CI 0.27-0.43); however, these studies used a variety of antihistamines and measured different outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of antihistamines (specifically H1-receptor blockers) was affirmed in a meta-analysis that examined the association between antihistamine use and major malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/40\">",
"     40",
"    </a>",
"    ]. This review of 24 controlled studies, including over 200,000 first trimester exposures, found that H1-receptor blockers appeared to have a protective effect on risk of malformations (OR 0.76, 95% CI 0.60-0.94).",
"   </p>",
"   <p>",
"    The primary mechanism of antihistamines in treatment of nausea and vomiting of pregnancy is direct inhibition of histamine at the histamine 1 (H1) receptor; the secondary mechanism is an indirect effect on the vestibular system by decreasing stimulation of the vomiting center. In addition, these agents inhibit the muscarinic receptor, which may mediate the emetic response.",
"   </p>",
"   <p>",
"    Side effects include sedation, dry mouth, lightheadedness, and constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217701\">",
"    <span class=\"h4\">",
"     Doxylamine succinate and pyridoxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, pyridoxine (vitamin B6) improves mild to moderate nausea, but does not significantly reduce vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15,27,36\">",
"     15,27,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pyridoxine (vitamin B6)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     Doxylamine",
"    </a>",
"    succinate is an antihistamine that is usually taken with pyridoxine. The combination appears to improve efficacy and was the formulation for Bendectin. Bendectin was voluntarily withdrawn from the market in 1983 due to lawsuits alleging teratogenicity, although scientific evidence supports its safety [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/41-43\">",
"     41-43",
"    </a>",
"    ] and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15,24,44-46\">",
"     15,24,44-46",
"    </a>",
"    ]. A meta-analysis of controlled studies on outcome of pregnancies exposed to Bendectin reported no increase in the incidence of birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/43\">",
"     43",
"    </a>",
"    ]. One evidence-based review of controlled studies concluded",
"    <span class=\"nowrap\">",
"     doxylamine/pyridoxine",
"    </span>",
"    is effective for treatment of nausea and vomiting in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/24\">",
"     24",
"    </a>",
"    ], while another such review did not find a significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Formulations similar to Bendectin are available outside the United States under various names (eg, Diclectin in Canada) and have been proven effective in placebo-controlled randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/47\">",
"     47",
"    </a>",
"    ]. We recommend these formulations, where available, for initial pharmacologic treatment of nausea of pregnancy. These drugs are available without a prescription.",
"   </p>",
"   <p>",
"    Initially, two delayed release tablets of Diclectin (a total of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    20 mg and pyridoxine 20 mg) are taken at bedtime. The dose may be increased to four tablets per day as needed for more severe nausea (one tablet in the morning, one tablet in the afternoon, two tablets at bedtime). In the United States, doxylamine is available in some over-the-counter sleeping pills (eg, Unisom Sleep Tabs) and as a prescription antihistamine chewable tablet (Aldex AN). One-half of the 25 mg over-the-counter tablet or two chewable 5 mg tablets can be used off-label as an antiemetic; pyridoxine 25 mg three to four times per day should be prescribed with it. The 10 mg dose of pyridoxine is not commercially available in the United States.",
"   </p>",
"   <p>",
"    Some pharmacies will provide the combination of pyridoxine 10 mg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    10 mg upon request.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389018\">",
"    <span class=\"h1\">",
"     SECONDARY APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218237\">",
"    <span class=\"h2\">",
"     Women without dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional oral medications can be initiated in women who can tolerate them. Non-oral routes of administration are useful for other women (",
"    <a class=\"graphic graphic_algorithm graphicRef74451 \" href=\"UTD.htm?7/48/7941\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219543\">",
"    <span class=\"h3\">",
"     First-line therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218526\">",
"    <span class=\"h4\">",
"     Antihistamines (H1 antagonists)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, only a few antihistamines have been studied for the treatment of nausea and vomiting of pregnancy (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Antihistamines (H1 antagonists)'",
"    </a>",
"    above). We suggest the following drugs as first-line agents for secondary therapy because they either have fewer maternal side effects or fetal safety is more well-established than other drugs.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    is stopped before starting a different antihistamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219195\">",
"    <span class=\"h5\">",
"     Diphenhydramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     Diphenhydramine",
"    </a>",
"    25 to 50 mg can be taken orally every four to six hours, as needed. It can also be given intravenously 10 to 50 mg every four to six hours, as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219472\">",
"    <span class=\"h5\">",
"     Meclizine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     Meclizine",
"    </a>",
"    25 mg can be taken orally every four to six hours, as needed. Meclizine has caused cleft palate in rats, but at exposures far higher than those used therapeutically. Human data of an association between facial clefts and meclizine have been mixed, but three large studies did not show an increased risk of malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218540\">",
"    <span class=\"h5\">",
"     Dimenhydrinate",
"    </span>",
"    &nbsp;&mdash;&nbsp;When oral medications are tolerated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    25 to 50 mg can be taken orally every four to six hours, as needed. Otherwise, 50 mg dimenhydrinate is administered intravenously over 20 minutes or 50 to 100 mg is administered rectally (where available) every four to six hours, as needed; the total dose should not exceed 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    If the woman is also taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    , the total dose of dimenhydrinate should not exceed 200",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219586\">",
"    <span class=\"h3\">",
"     Second-line therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218554\">",
"    <span class=\"h4\">",
"     Dopamine antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on their safety profile, we consider these drugs second-line agents for secondary treatment of nausea and vomiting of pregnancy.",
"   </p>",
"   <p>",
"    During nausea and vomiting, dopamine receptors in the stomach mediate the inhibition of gastric motility and, therefore, may provide a site of action for antiemetic dopamine receptor antagonists. Dopamine, specifically at the dopamine 2 receptors, is also implicated in emetic signaling through the chemoreceptor trigger zone.",
"   </p>",
"   <p>",
"    Several types of dopamine antagonists can be used for the treatment of nausea and vomiting of pregnancy. The three main classes of dopamine receptor antagonists are phenothiazines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ), butyrophenones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ), and benzamides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218624\">",
"    <span class=\"h5\">",
"     Prochlorperazine and chlorpromazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     Prochlorperazine",
"    </a>",
"    5 to 10 mg orally, intravenously, or intramuscularly every six hours or 25 mg per rectum twice per day, as needed, appears to benefit some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/51\">",
"     51",
"    </a>",
"    ]. Safety information is limited: although case reports of malformations in exposed infants have been published, larger series have not reported an increased risk of birth defects. Results from animal studies vary depending on the animal exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We reserve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    for refractory cases, given its profile of adverse side effects (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Refractory patients'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219751\">",
"    <span class=\"h5\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    10 mg orally, intravenously, or intramuscularly (ideally 30 minutes prior to meal and at bedtime) every six to 8 hours is commonly prescribed for nausea and vomiting related to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/53\">",
"     53",
"    </a>",
"    ]. In the only randomized trial evaluating this drug in women with hyperemesis, metoclopramide 10 mg was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    25 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (1.2 to 1.8",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    intravenously) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg every six hours) reported vomiting improved in 36 percent of patients and was more effective than the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/hour)",
"    </span>",
"    plus diphenhydramine, which had been used in previous patient cohorts. In another series, combination therapy with metoclopramide and pyridoxine was superior to monotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    in decreasing the number of vomiting episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large cohort study of 3458 infants exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    during the first trimester of pregnancy found no significant increase in risk of major congenital malformations, low birth weight, preterm delivery, or perinatal death compared with nonexposed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/55\">",
"     55",
"    </a>",
"    ]. These findings persisted when therapeutic abortions of exposed and unexposed fetuses were included in the analysis.",
"   </p>",
"   <p>",
"    Maternal side effects are a concern, especially with long-term use.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    accounts for almost one third of all drug-induced movement disorders and female sex is a risk factor for development of these side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/56\">",
"     56",
"    </a>",
"    ]. However, in the randomized trial discussed above, dystonia was more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    than metoclopramide",
"    <span class=\"nowrap\">",
"     (14/73",
"    </span>",
"    [19.2 percent] versus",
"    <span class=\"nowrap\">",
"     4/70",
"    </span>",
"    [5.7 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/54\">",
"     54",
"    </a>",
"    ]. Upon discontinuation of the drug, metoclopramide-induced tardive dyskinesia (involuntary and repetitive movements of the body) can be irreversible in some cases. Early detection and discontinuation of the metoclopramide are important for the prevention of permanent tardive dyskinesia. Use of metoclopramide with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    may mask a dystonic reaction.",
"   </p>",
"   <p>",
"    The use of subcutaneous pumps for timed release of medications, in particular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , has been reported for outpatient management of nausea and vomiting in pregnancy with some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the experience is limited; we do not use them.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    is another promotility agent, but there is no information on its safety or efficacy for treatment of nausea and vomiting of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88183937\">",
"    <span class=\"h5\">",
"     Promethazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     Promethazine",
"    </a>",
"    is primarily an H1 receptor blocking agent, but is also a weak dopamine antagonist. Promethazine 12.5 to 25 mg can be given orally, per rectum, or intramuscularly every four hours. Oral or rectal administration is preferred. Intraarterial, intravenous, and subcutaneous administration is contraindicated, as inadvertent intraarterial injection can result in gangrene of the affected extremity and subcutaneous injection may result in tissue necrosis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal safety [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/52\">",
"     52",
"    </a>",
"    ] and maternal efficacy in relief of both nausea and vomiting have been demonstrated in large groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/15,24,40,54,58-60\">",
"     15,24,40,54,58-60",
"    </a>",
"    ]. Disadvantages include prominent sedation and risk of dystonic reactions. These risks are elevated under conditions of prolonged use and high dosing. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    appears to lower the seizure threshold, which may be important late in pregnancy in women with preeclampsia. There are conflicting reports regarding a potential risk of neonatal respiratory depression following the administration of promethazine during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/52\">",
"     52",
"    </a>",
"    ]. Neonatal platelet aggregation also may be impaired when the drug is given intrapartum, but this does not appear to increase the need for intervention in the newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218631\">",
"    <span class=\"h5\">",
"     Droperidol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     Droperidol",
"    </a>",
"    is used as an antiemetic in surgical and diagnostic procedures. In one study, patients with hyperemesis gravidarum treated with droperidol-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    had significantly shorter hospitalizations (3.1 versus 3.8 days), fewer days per pregnancy hospitalized for hyperemesis (3.5 versus 4.8 days), and fewer readmissions with this diagnosis (15.0 versus 31.5 percent) than women treated with other parenteral therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/61\">",
"     61",
"    </a>",
"    ]. No congenital anomalies were reported in 108 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/52\">",
"     52",
"    </a>",
"    ]. However, maternal side effects are a concern, especially with long-term use. Droperidol has been associated with QT prolongation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    torsades de pointes when used in doses higher than those typically used for treatment of nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/62\">",
"     62",
"    </a>",
"    ]. A discussion of a new drug warning for droperidol can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We rarely use this drug to treat nausea and vomiting of pregnancy because of these safety concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218645\">",
"    <span class=\"h4\">",
"     Serotonin antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     Ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    are selective antagonists at the 5-HT3 serotonin receptor. This class of drug has a favorable efficacy-safety profile in non-pregnant individuals with nausea and vomiting of various etiologies and severities. Animal data on ondansetron are reassuring as to its safety in pregnancy. Human data on safety or efficacy of ondansetron for treatment of hyperemesis are based on case reports, small series and a historical cohort of 1849 women in Denmark exposed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/24,63-68\">",
"     24,63-68",
"    </a>",
"    ]. Ondansetron has not been associated with an increased risk of congenital anomalies, miscarriage, low birth weight, or other adverse outcomes when used for treatment of nausea and vomiting of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/63,68\">",
"     63,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no human data on the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    or other 5-HT3 antagonists in pregnancy; animal studies did not show adverse pregnancy effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30154769\">",
"    <span class=\"h5\">",
"     Ondansetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     Ondansetron",
"    </a>",
"    4 to 8 mg can be taken orally every eight hours, as needed, or administered intravenously by bolus injection every eight hours, as needed. Headache, fatigue, constipation, and drowsiness are the most common side effects. Hyperemesis is a common unlabeled indication for use. Ondansetron can cause QT prolongation, particularly in patients with underlying heart conditions, such as congenital long QT syndrome; patients with hypokalemia or hypomagnesemia; and those taking other medications that lead to QT prolongation. ECG monitoring is recommended in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218715\">",
"    <span class=\"h3\">",
"     Adjunctive therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218723\">",
"    <span class=\"h4\">",
"     Acid reducing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid reducing medications can be used as adjunctive therapy. In women with",
"    <span class=\"nowrap\">",
"     heartburn/acid",
"    </span>",
"    reflux and",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    of pregnancy, an observational study found that acid-reducing pharmacotherapy (eg, antacids, H2 blockers, proton pump inhibitors) combined with anti-emetic therapy resulted in significant improvement in symptoms and well-being three to four days after beginning therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antacids containing aluminum or calcium are safe and preferable to those containing bismuth or bicarbonate, which may have adverse",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest experience with pharmacologic acid-suppressive therapy in pregnant women has been with the H2 receptor antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    &nbsp;and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , which appear to be safe during pregnancy. The efficacy of ranitidine 150 mg orally twice daily for treatment of acid reflux was demonstrated in a placebo-controlled, double-blind trial of 20 pregnant women whose heartburn was refractory to conservative measures; heartburn severity was reduced 44 percent compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less experience using proton pump inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    30 or 40 mg intravenously or orally every 24 hours) during pregnancy, but they are probably safe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217940\">",
"    <span class=\"h2\">",
"     Women with dehydration, electrolyte abnormalities, acid-base abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are unable to maintain adequate hydration, normal electrolyte levels, and acid-base balance with the initial interventions described above should be admitted to the hospital for intravenous fluids and medications. We admit women to the hospital if they have persistent vomiting after rehydration and fail outpatient management. Women who have severe vomiting, weight loss, ketonuria, dry mucous membranes, poor skin turgor, dehydration, hypotension, alkalosis from hydrochloric acid loss, hypokalemia, or nutritional deficiencies are admitted to the hospital. In women with persistent vomiting after hospitalization, it is important to exclude underlying diseases that can cause hyperemesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients and their families often need emotional support to help deal with stress and anxiety about the maternal illness and its effect on the fetus, and the disruption to their home- and work-related activities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/71\">",
"     71",
"    </a>",
"    ]. In some cases, psychiatric consultation can be helpful to teach the patient relaxation and coping techniques and address underlying psychopathology, if present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389638\">",
"    <span class=\"h3\">",
"     Fluids and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients respond to intravenous hydration and a short period of gut rest, followed by reintroduction of oral intake and pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389666\">",
"    <span class=\"h4\">",
"     Fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydration occurs when fluid output exceeds fluid intake and is often associated with electrolyte abnormalities, fatigue, dizziness, and weakness. We correct dehydration with up to 2 L intravenous Ringer&rsquo;s lactate infused over three to five hours, supplemented with appropriate electrolytes and vitamins. Subsequently, the infusion rate is adjusted to maintain a urine output of at least 100",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    and the solution is changed to dextrose 5% in 0.45% saline. The optimum replacement fluid regimen has not been studied. It is prudent to avoid use of dextrose in the initial rehydration fluid because of the theoretical concern of Wernicke&rsquo;s encephalopathy with dextrose infusion in a thiamine-deficient state [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/73\">",
"     73",
"    </a>",
"    ]. We delay dextrose infusion until after the patient has received thiamine in her initial rehydration fluid (see",
"    <a class=\"local\" href=\"#H21389680\">",
"     'Vitamins and minerals'",
"    </a>",
"    below). A single small study did not observe adverse effects in 102 patients who received intravenous thiamine followed by 5% dextrose 0.9% saline for persistent nausea and vomiting of pregnancy; however, only 60 percent of these women had severe disease (ie, weight loss &ge;5 percent body weight, ketonuria 4+) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relief of symptoms is common within one to two days of rehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/7\">",
"     7",
"    </a>",
"    ]. Hospitalization, as well as replenishment of fluids and electrolytes, may contribute to palliation of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389680\">",
"    <span class=\"h4\">",
"     Vitamins and minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is experiencing persistent vomiting, it is important to replenish low levels of vitamins (especially thiamine), electrolytes, and minerals (ie, magnesium, calcium, and phosphorous) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/75\">",
"     75",
"    </a>",
"    ]. We provide thiamine (vitamin B1) supplementation by giving 100 mg intravenously with the initial rehydration fluids and another 100 mg daily for the next two or three days. Early administration of thiamine is important to prevent a rare maternal complication, Wernicke's encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/7,76\">",
"     7,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each day we administer a multivitamin (MVI) intravenously: MVI (10 mL) plus 0.6 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (to bring the folic acid total to 1 mg) in one liter and vitamin B6 25 mg in every liter. The intravenous fluid is usually dextrose 5% in 0.45% saline with 20 mEq",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    given at 150",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Hypomagnesemia is a common cause of hypocalcemia. We first correct the low magnesium level by giving 2 grams (16 meq)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    infused as a 10% solution over 10 to 20 minutes, followed by 1 gram (8 meq) in 100 mL of fluid per hour. The repletion of magnesium is continued if the serum magnesium level is less than 0.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 0.4",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Once serum magnesium levels are restored, we reassess the calcium level. If serum calcium is still low, we administer 1 to 2 grams",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    in 50 mL of 5% dextrose solution over 10 to 20 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21389950\">",
"    <span class=\"h4\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diet that attempts to minimize nausea and vomiting can be resumed after a short period of gut rest. We usually begin women on a diet consisting of bananas, rice, applesauce, and toast (BRAT diet) and then advance their diet as tolerated. Consistent protein intake is key in helping prevent nausea. Additional dietary manipulations are described above. (See",
"    <a class=\"local\" href=\"#H21389346\">",
"     'Diet'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have not eaten for several days may develop edema when resuming feeding with carbohydrates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/77\">",
"     77",
"    </a>",
"    ]. This results from the retention of sodium during fasting combined with enhanced sodium resorption due to the actions of insulin once carbohydrates are reintroduced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/78\">",
"     78",
"    </a>",
"    ]. No intervention is required; the edema will gradually resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21390012\">",
"    <span class=\"h2\">",
"     Oral and non-oral medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral medications can be initiated in women who can tolerate them. Non-oral routes of administration are useful for other women. These medications are the same as those used to treat women without dehydration (",
"    <a class=\"graphic graphic_algorithm graphicRef74451 \" href=\"UTD.htm?7/48/7941\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H218237\">",
"     'Women without dehydration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     REFRACTORY PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7475644\">",
"    <span class=\"h2\">",
"     Chlorpromazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    (25 to 50 mg intravenously or intramuscularly or 10 to 25 mg orally every four to six hours) to be helpful in refractory cases. A rectal suppository may be available in some countries. Adverse effects include extrapyramidal reactions, orthostatic hypotension, anticholinergic effects, and altered cardiac conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7475442\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have been used in women with severe and refractory hyperemesis, although the mechanism of action is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. There is a paucity of evidence that glucocorticoids are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/24,83\">",
"     24,83",
"    </a>",
"    ]. The largest placebo controlled trial included 110 women with severe hyperemesis and reported that women who received glucocorticoid therapy had a similar clinical course and need for rehospitalization as those given placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid use has been associated with a slightly increased risk of oral clefts when the drug is administered before 10 weeks of gestation; therefore, ideally, use of glucocorticoids should be avoided in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. If administered after 10 weeks, the palate has formed and is not at risk for developing defects.",
"   </p>",
"   <p>",
"    An effective dose is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (16 mg) intravenously every 8 hours for 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/79\">",
"     79",
"    </a>",
"    ]. Methylprednisolone can be stopped abruptly if there is no response, and tapered over two weeks in women who experience relief of symptoms. After intravenous therapy, we use an oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper regimen of 40 mg oral prednisone per day for one day, followed by 20 mg per day for three days, followed by 10 mg per day for three days, and then 5 mg per day for seven days. This regimen may be repeated up to three times over a six week period.",
"   </p>",
"   <p>",
"    Glucocorticoids should be reserved for treatment of refractory nausea and vomiting of pregnancy or hyperemesis gravidarum, given the risk of maternal side effects and uncertain efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7475767\">",
"    <span class=\"h2\">",
"     Enteral and parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are refractory to all pharmacologic and nonpharmacologic interventions should be supported with enteral (tube feedings) or parenteral nutrition and intravenous fluids as long as necessary. We continue such women on pharmacologic interventions that seem to provide some relief of their nausea and vomiting.",
"   </p>",
"   <p>",
"    Nutritional status and methods of alimentation (eg, tube feedings, parenteral nutrition) should be assessed in conjunction with a nutritionist or nutrition service. The optimal timing for initiating enteral or parenteral nutrition has not been established; the decision is based upon clinical judgment. In general, enteral nutrition is begun in women who cannot maintain their weight because of vomiting and despite a trial of the interventions described below. Enteral nutrition via gastric or duodenal intubation is preferable to the parenteral route and may relieve the nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/90\">",
"     90",
"    </a>",
"    ]. Adequate protein-caloric parenteral nutrition requires a central venous access device (CVAD), which may lead to catheter-related infection or thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) technical review for parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/92\">",
"     92",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222950\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF STABLE AND IMPROVING PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We continue the drug regimen that has been effective until the patient has been completely asymptomatic (no nausea or vomiting) for at least a week. At that time, we discontinue the medications and see how she does. If nausea and vomiting recurs, we resume therapy. The majority of women will have resolution of nausea and vomiting by 16 to 20 weeks of gestation and will be able to discontinue their medications. Rare patients require therapy beyond 20 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550221342\">",
"    <span class=\"h2\">",
"     Short-term outcomes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550221006\">",
"    <span class=\"h3\">",
"     Nausea and vomiting of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the maternal course can be long and tedious [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/93\">",
"     93",
"    </a>",
"    ], nausea and vomiting is typically not associated with adverse pregnancy outcomes. There is good evidence that women with nausea and vomiting in early pregnancy have a lower rate of miscarriage than women without these symptoms. In one meta-analysis, the odds of miscarriage in women with nausea and vomiting in the first 20 weeks of pregnancy was OR 0.36 (95% CI 0.2-0.42) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/94\">",
"     94",
"    </a>",
"    ]. However, the analysis did not correlate outcome with respect to the severity of the disorder. Most of the women in these studies had mild symptoms, rather than hyperemesis.",
"   </p>",
"   <p>",
"    The frequency of congenital anomalies is not increased among offspring of gravida with nausea and vomiting in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/95\">",
"     95",
"    </a>",
"    ], whether or not they take antiemetic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/58,96-100\">",
"     58,96-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550221100\">",
"    <span class=\"h3\">",
"     Hyperemesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the potential severity of nausea and vomiting and its attendant early weight loss, most studies have reported no difference in birth weight or gestational age at birth between affected pregnancies and those unaffected by vomiting, as long as prepregnancy weight was normal and there was \"catch-up\" weight gain later in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/97,98,101\">",
"     97,98,101",
"    </a>",
"    ]. In contrast, women with severe vomiting who require multiple hospitalizations may not have \"catch up\" weight gain; an adverse effect on birthweight is more likely in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/96,102-105\">",
"     96,102-105",
"    </a>",
"    ]. Women who have less than 7 kg weight gain are more likely to have a preterm",
"    <span class=\"nowrap\">",
"     birth/low",
"    </span>",
"    birth weight infant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. When studies of women with hyperemesis gravidarum were pooled without regard to prepregnancy weight or catch-up weight gain, the risks of preterm delivery, low birth weight (LBW), and birth of a small for gestational age (SGA) infant were slightly but significantly increased (preterm delivery OR 1.32, 95% CI 1.04-1.68; LBW OR 1.42, 95% CI 1.27-1.58, SGA OR 1.28, 95% CI 1.02-1.60, 17.9 versus 12.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between second trimester hyperemesis gravidarum and placental dysfunction (eg, preeclampsia, abruption, SGA) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/107\">",
"     107",
"    </a>",
"    ], but an increased risk of perinatal death has not been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of parenteral and enteral nutrition has reduced maternal morbidity, and mortality is virtually nonexistent in women who are treated. If left untreated, there have been reports of sequelae of micronutrient deficiency (eg, most commonly Wernicke encephalopathy from deficiency of vitamin B1; possibly very rare bleeding diathesis or embryopathy from vitamin K deficiency) and adverse effects of malnutrition (immunosuppression, poor wound healing, muscle wasting) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/76,102,108-112\">",
"     76,102,108-112",
"    </a>",
"    ]. Esophageal tears (Mallory-Weiss), esophageal rupture, pneumothoraces, pneumomediastinum, osmotic demyelination syndrome (formerly known as central pontine myelinolysis), hepatic insufficiency, and acute tubular necrosis are other rare complications in women with persistent severe vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/113-115\">",
"     113-115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is, however, psychosocial morbidity, including substantial effects on ability to work outside the home, household duties, parenting activities, and social interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/116-119\">",
"     116-119",
"    </a>",
"    ]. The burdens of caregiver-time and use of health care resources also need to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550221285\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although long-term follow-up data are limited, one small observational cohort study found no evidence of neurodevelopmental delay in 3 to 7 year old children of mothers with nausea and vomiting of pregnancy treated with pyridoxine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    succinate or untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/120\">",
"     120",
"    </a>",
"    ]. A small case-control study observed an association between hyperemesis gravidarum and development of testicular cancer before age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/121\">",
"     121",
"    </a>",
"    ]. Larger follow-up studies are needed to determine whether nausea and vomiting of pregnancy has long-term effects on offspring. These studies need to use well-defined criteria for the severity of the disease, and adjust for key maternal characteristics, such as prepregnancy weight and weight gain during pregnancy. Metabolic and cardiovascular outcomes should be evaluated since small for gestational age birth has been linked to chronic disease in adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no good data on long-term maternal outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83690964\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disorder is likely to recur in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/105,123-125\">",
"     105,123-125",
"    </a>",
"    ]. Two population based series reported the risk of recurrent hyperemesis in a second pregnancy was 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/123\">",
"     123",
"    </a>",
"    ] and 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/105\">",
"     105",
"    </a>",
"    ] percent in women with previous hyperemesis, but only 0.7 percent in women with no such history [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/123\">",
"     123",
"    </a>",
"    ]. Another study contacted women who had one pregnancy complicated by hyperemesis gravidarum and registered on an internet site sponsored by the Hyperemesis Education and Research Foundation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/124\">",
"     124",
"    </a>",
"    ]. Of 100 respondents, 57 had become pregnant again, of whom 46 experienced recurrent severe nausea and vomiting; 37 women reported that they did not want to get pregnant a second time because of the recurrence risk of hyperemesis gravidarum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, all women of child-bearing age should be advised to take a daily multivitamin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    beginning in the preconception period; this reduces the risk of congenital anomalies, particularly neural tube defects, and may help to decrease the frequency and severity of nausea and vomiting during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. The positive effects of multivitamins are likely due to the general optimization of nutritional status and metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, heartburn and acid reflux have been associated with increased severity of nausea and vomiting of pregnancy, which suggests that managing these disorders prior to pregnancy might prevent or reduce the severity of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/20/29002/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/39/1650?source=see_link\">",
"       \"Patient information: Morning sickness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=see_link\">",
"       \"Patient information: Taking over-the-counter medicines during pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/7/4210?source=see_link\">",
"       \"Patient information: Hyperemesis gravidarum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=see_link\">",
"       \"Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A step-wise approach to treatment of nausea and vomiting of pregnancy is provided in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef74451 \" href=\"UTD.htm?7/48/7941\">",
"     algorithm 1",
"    </a>",
"    ). The steps are based on evidence of efficacy and safety profiles. The goal is to reduce symptoms through changes in",
"    <span class=\"nowrap\">",
"     diet/environment",
"    </span>",
"    and by medication, correct consequences or complications of nausea and vomiting, and minimize the fetal effects of maternal nausea and vomiting and its treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should try to become aware of, and avoid, environmental triggers and foods which might provoke their nausea and vomiting. (See",
"      <a class=\"local\" href=\"#H21389041\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acupuncture and acupressure have not been proven to significantly reduce nausea and vomiting. However, given the absence of harm and the strong placebo effect, some patients may benefit from a trial of acupressure wrist bands. Patient preferences should guide therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acupuncture and acupressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available, we suggest pyridoxine-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/52/17221?source=see_link\">",
"       doxylamine",
"      </a>",
"      succinate combination therapy for initial pharmacologic treatment of nausea of pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If this drug is not available, we suggest pyridoxine, adding doxylamine succinate if pyridoxine alone is not effective. (See",
"      <a class=\"local\" href=\"#H217701\">",
"       'Doxylamine succinate and pyridoxine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Pyridoxine (vitamin B6)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If nausea and vomiting persists, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      25 to 50 mg orally every four to six hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"       meclizine",
"      </a>",
"      25 mg orally every six hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If symptoms do not improve, we suggest adding a dopamine antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H218554\">",
"       'Dopamine antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require hospitalization because of dehydration, we suggest a serotonin antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H218645\">",
"       'Serotonin antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who are dehydrated or have electrolyte abnormalities or acid-base disturbances should receive intravenous fluids. Thiamine supplements should be added to the intravenous solution to prevent Wernicke's encephalopathy. We suggest a short period of gut rest during hydration, followed by reintroduction of oral intake with liquids and bland, low fat foods. (See",
"      <a class=\"local\" href=\"#H21389638\">",
"       'Fluids and nutrition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21389346\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We reserve use of glucocorticoids for treatment of refractory cases after the first trimester. (See",
"      <a class=\"local\" href=\"#H7475442\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal timing for initiating enteral or parenteral nutrition has not been established; the decision is based upon clinical judgment. In general, enteral nutrition is begun in women who cannot maintain their weight because of vomiting and despite a step-wise trial of pharmacologic interventions. (See",
"      <a class=\"local\" href=\"#H7475767\">",
"       'Enteral and parenteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that women of child-bearing age take a multivitamin with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      to help prevent nausea and vomiting during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), as well as for reducing the risk of neural tube defects. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/1\">",
"      American College of Obstetrics and Gynecology. ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol 2004; 103:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/2\">",
"      Bischoff SC, Renzer C. Nausea and nutrition. Auton Neurosci 2006; 129:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/3\">",
"      Newman V, Fullerton JT, Anderson PO. Clinical advances in the management of severe nausea and vomiting during pregnancy. J Obstet Gynecol Neonatal Nurs 1993; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/4\">",
"      Duncan JW, Harding VJ. A report on the effect of high carbohydrate feeding on the nausea and vomiting of pregnancy. Can Med Assoc J 1918; 8:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/5\">",
"      Jednak MA, Shadigian EM, Kim MS, et al. Protein meals reduce nausea and gastric slow wave dysrhythmic activity in first trimester pregnancy. Am J Physiol 1999; 277:G855.",
"     </a>",
"    </li>",
"    <li>",
"     Erick, M. No More Morning Sickness: A Survival Guide for Pregnant Women. Plume, New York 1993.",
"    </li>",
"    <li>",
"     Association of professors of gynecology and obstetrics. Nausea and vomiting of pregnancy. Association of professors of gynecology and obstetrics, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/8\">",
"      Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004; 2:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/9\">",
"      Heinrichs L. Linking olfaction with nausea and vomiting of pregnancy, recurrent abortion, hyperemesis gravidarum, and migraine headache. Am J Obstet Gynecol 2002; 186:S215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/10\">",
"      Erick M. Hyperolfaction and hyperemesis gravidarum: what is the relationship? Nutr Rev 1995; 53:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/11\">",
"      Arsenault MY, Lane CA, MacKinnon CJ, et al. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can 2002; 24:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/12\">",
"      Gill SK, Maltepe C, Koren G. The effectiveness of discontinuing iron-containing prenatal multivitamins on reducing the severity of nausea and vomiting of pregnancy. J Obstet Gynaecol 2009; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/13\">",
"      Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician 2007; 53:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/14\">",
"      Roscoe JA, Matteson SE. Acupressure and acustimulation bands for control of nausea: a brief review. Am J Obstet Gynecol 2002; 186:S244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/15\">",
"      Matthews A, Dowswell T, Haas DM, et al. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2010; :CD007575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/16\">",
"      Werntoft E, Dykes AK. Effect of acupressure on nausea and vomiting during pregnancy. A randomized, placebo-controlled, pilot study. J Reprod Med 2001; 46:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/17\">",
"      Knight B, Mudge C, Openshaw S, et al. Effect of acupuncture on nausea of pregnancy: a randomized, controlled trial. Obstet Gynecol 2001; 97:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/18\">",
"      Dundee JW, Sourial FB, Ghaly RG, Bell PF. P6 acupressure reduces morning sickness. J R Soc Med 1988; 81:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/19\">",
"      O'Brien B, Relyea MJ, Taerum T. Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. Am J Obstet Gynecol 1996; 174:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/20\">",
"      Rosen T, de Veciana M, Miller HS, et al. A randomized controlled trial of nerve stimulation for relief of nausea and vomiting in pregnancy. Obstet Gynecol 2003; 102:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/21\">",
"      Simon EP, Schwartz J. Medical hypnosis for hyperemesis gravidarum. Birth 1999; 26:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/22\">",
"      Henker FO 3rd. Psychotherapy as adjunct in treatment of vomiting during pregnancy. South Med J 1976; 69:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/23\">",
"      Zechnich R, Hammer T. Brief psychotherapy for hyepremesis gravidarum. Am Fam Physician 1982; 26:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/24\">",
"      Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002; 186:S256.",
"     </a>",
"    </li>",
"    <li>",
"     Einarson, A, Maltepe, C, Boskovic, R, Koren, G. Treatment of nausea and vomiting in pregnancy. An updated algorithm file://www.motherisk.org/documents/Revised_NVP_Algorithm.pdf (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/26\">",
"      Badell ML, Ramin SM, Smith JA. Treatment options for nausea and vomiting during pregnancy. Pharmacotherapy 2006; 26:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/27\">",
"      Niebyl JR, Goodwin TM. Overview of nausea and vomiting of pregnancy with an emphasis on vitamins and ginger. Am J Obstet Gynecol 2002; 186:S253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/28\">",
"      Willetts KE, Ekangaki A, Eden JA. Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2003; 43:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/29\">",
"      Portnoi G, Chng LA, Karimi-Tabesh L, et al. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol 2003; 189:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/30\">",
"      Smith C, Crowther C, Willson K, et al. A randomized controlled trial of ginger to treat nausea and vomiting in pregnancy. Obstet Gynecol 2004; 103:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/31\">",
"      Borrelli F, Capasso R, Aviello G, et al. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 2005; 105:849.",
"     </a>",
"    </li>",
"    <li>",
"     Reprotox. Ginger. www.reprotox.com (Accessed on August 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/33\">",
"      Schwertner HA, Rios DC, Pascoe JE. Variation in concentration and labeling of ginger root dietary supplements. Obstet Gynecol 2006; 107:1337.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm196045.htm. (Accessed January 4, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/35\">",
"      Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol 1991; 78:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/36\">",
"      Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. J Obstet Gynaecol 2004; 24:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/37\">",
"      Reeve BK, Cook DJ, Babineau D, et al. Prophylactic Diclectin reduces the incidence of postoperative vomiting. Can J Anaesth 2005; 52:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/38\">",
"      Schuster K, Bailey LB, Dimperio D, Mahan CS. Morning sickness and vitamin B6 status of pregnant women. Hum Nutr Clin Nutr 1985; 39:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/39\">",
"      Cobble CR. Traumatic expulsion of lens. J Am Intraocul Implant Soc 1982; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/40\">",
"      Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/41\">",
"      Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health 1995; 86:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/42\">",
"      Brent RL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 1995; 9:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/43\">",
"      McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994; 50:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/44\">",
"      GEIGER CJ, FAHRENBACH DM, HEALEY FJ. Bendectin in the treatment of nausea and vomiting in pregnancy. Obstet Gynecol 1959; 14:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/45\">",
"      Wheatley D. Treatment of pregnancy sickness. Br J Obstet Gynaecol 1977; 84:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/46\">",
"      McGuinness BW, Binns DT. 'Debendox' in pregnancy sickness. J R Coll Gen Pract 1971; 21:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/47\">",
"      Koren G, Clark S, Hankins GD, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 2010; 203:571.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/48\">",
"      Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. Am J Obstet Gynecol 1965; 93:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/49\">",
"      Milkovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976; 125:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/50\">",
"      Shapiro S, Kaufman DW, Rosenberg L, et al. Meclizine in pregnancy in relation to congenital malformations. Br Med J 1978; 1:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/51\">",
"      Bsat FA, Hoffman DE, Seubert DE. Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy. J Perinatol 2003; 23:531.",
"     </a>",
"    </li>",
"    <li>",
"     www.Reprotox.org. (Accessed March 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/53\">",
"      Einarson A, Koren G, Bergman U. Nausea and vomiting in pregnancy: a comparative European study. Eur J Obstet Gynecol Reprod Biol 1998; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/54\">",
"      Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol 2010; 115:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/55\">",
"      Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009; 360:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/56\">",
"      Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 3:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/57\">",
"      Buttino L Jr, Coleman SK, Bergauer NK, et al. Home subcutaneous metoclopramide therapy for hyperemesis gravidarum. J Perinatol 2000; 20:359.",
"     </a>",
"    </li>",
"    <li>",
"     Kallen, B. Hyperemesis gravidarum during pregnancy and delivery: A registry study. In: Nausea and Vomiting of Pregnancy: State of the Art 2000, Koren, G, Bishai, R (Eds), Motherisk, Toronto 2000. p.36.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/59\">",
"      Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. Acad Emerg Med 2008; 15:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/60\">",
"      FITZGERALD JP. The effect of promethazine in nausea and vomiting of pregnancy. N Z Med J 1955; 54:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/61\">",
"      Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol 1996; 174:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/62\">",
"      Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm 2007; 64:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/63\">",
"      Einarson A, Maltepe C, Navioz Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004; 111:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/64\">",
"      Siu SS, Yip SK, Cheung CW, Lau TK. Treatment of intractable hyperemesis gravidarum by ondansetron. Eur J Obstet Gynecol Reprod Biol 2002; 105:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/65\">",
"      Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 1996; 72:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/66\">",
"      Sullivan CA, Johnson CA, Roach H, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996; 174:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/67\">",
"      Siu SS, Chan MT, Lau TK. Placental transfer of ondansetron during early human pregnancy. Clin Pharmacokinet 2006; 45:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/68\">",
"      Pasternak B, Svanstr&ouml;m H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013; 368:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/69\">",
"      Gill SK, Maltepe C, Mastali K, Koren G. The effect of Acid-reducing pharmacotherapy on the severity of nausea and vomiting of pregnancy. Obstet Gynecol Int 2009; 2009:585269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/70\">",
"      Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol 2007; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/71\">",
"      Deuchar N. Nausea and vomiting in pregnancy: a review of the problem with particular regard to psychological and social aspects. Br J Obstet Gynaecol 1995; 102:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/72\">",
"      Lub-Moss MM, Eurelings-Bontekoe EH. Clinical experience with patients suffering from hyperemesis gravidarum (severe nausea and vomiting during pregnancy): thoughts about subtyping of patients, treatment and counseling models. Patient Educ Couns 1997; 31:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/73\">",
"      Jarvis S, Nelson-Piercy C. Management of nausea and vomiting in pregnancy. BMJ 2011; 342:d3606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/74\">",
"      Tan PC, Norazilah MJ, Omar SZ. Dextrose saline compared with normal saline rehydration of hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol 2013; 121:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/75\">",
"      Brooks MJ, Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy 1995; 15:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/76\">",
"      Chiossi G, Neri I, Cavazzuti M, et al. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv 2006; 61:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/77\">",
"      Veverbrants E, Arky RA. Effects of fasting and refeeding. I. Studies on sodium, potassium and water excretion on a constant electrolyte and fluid intake. J Clin Endocrinol Metab 1969; 29:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/78\">",
"      DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/79\">",
"      Safari HR, Alsulyman OM, Gherman RB, Goodwin TM. Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. Am J Obstet Gynecol 1998; 178:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/80\">",
"      Taylor R. Successful management of hyperemesis gravidarum using steroid therapy. QJM 1996; 89:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/81\">",
"      Nelson-Piercy C, Fayers P, de Swiet M. Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. BJOG 2001; 108:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/82\">",
"      Moran P, Taylor R. Management of hyperemesis gravidarum: the importance of weight loss as a criterion for steroid therapy. QJM 2002; 95:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/83\">",
"      Ziaei S, Hosseiney FS, Faghihzadeh S. The efficacy low dose of prednisolone in the treatment of hyperemesis gravidarum. Acta Obstet Gynecol Scand 2004; 83:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/84\">",
"      Yost NP, McIntire DD, Wians FH Jr, et al. A randomized, placebo-controlled trial of corticosteroids for hyperemesis due to pregnancy. Obstet Gynecol 2003; 102:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/85\">",
"      Shepard TH, Brent RL, Friedman JM, et al. Update on new developments in the study of human teratogens. Teratology 2002; 65:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/86\">",
"      Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/87\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/88\">",
"      Rodr&iacute;guez-Pinilla E, Mart&iacute;nez-Fr&iacute;as ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998; 58:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/89\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003; 67:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/90\">",
"      Hsu JJ, Clark-Glena R, Nelson DK, Kim CH. Nasogastric enteral feeding in the management of hyperemesis gravidarum. Obstet Gynecol 1996; 88:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/91\">",
"      Holmgren C, Aagaard-Tillery KM, Silver RM, et al. Hyperemesis in pregnancy: an evaluation of treatment strategies with maternal and neonatal outcomes. Am J Obstet Gynecol 2008; 198:56.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/92\">",
"      Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/93\">",
"      Tan PC, Jacob R, Quek KF, Omar SZ. Indicators of prolonged hospital stay in hyperemesis gravidarum. Int J Gynaecol Obstet 2006; 93:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/94\">",
"      Weigel RM, Weigel MM. Nausea and vomiting of early pregnancy and pregnancy outcome. A meta-analytical review. Br J Obstet Gynaecol 1989; 96:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/95\">",
"      Veenendaal MV, van Abeelen AF, Painter RC, et al. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG 2011; 118:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/96\">",
"      K&auml;ll&eacute;n B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol 1987; 26:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/97\">",
"      Hallak M, Tsalamandris K, Dombrowski MP, et al. Hyperemesis gravidarum. Effects on fetal outcome. J Reprod Med 1996; 41:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/98\">",
"      Tsang IS, Katz VL, Wells SD. Maternal and fetal outcomes in hyperemesis gravidarum. Int J Gynaecol Obstet 1996; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/99\">",
"      Boneva RS, Moore CA, Botto L, et al. Nausea during pregnancy and congenital heart defects: a population-based case-control study. Am J Epidemiol 1999; 149:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/100\">",
"      Klebanoff MA, Mills JL. Is vomiting during pregnancy teratogenic? Br Med J (Clin Res Ed) 1986; 292:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/101\">",
"      Flaxman SM, Sherman PW. Morning sickness: a mechanism for protecting mother and embryo. Q Rev Biol 2000; 75:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/102\">",
"      Paauw JD, Bierling S, Cook CR, Davis AT. Hyperemesis gravidarum and fetal outcome. JPEN J Parenter Enteral Nutr 2005; 29:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/103\">",
"      Bailit JL. Hyperemesis gravidarium: Epidemiologic findings from a large cohort. Am J Obstet Gynecol 2005; 193:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/104\">",
"      Depue RH, Bernstein L, Ross RK, et al. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am J Obstet Gynecol 1987; 156:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/105\">",
"      Dodds L, Fell DB, Joseph KS, et al. Outcomes of pregnancies complicated by hyperemesis gravidarum. Obstet Gynecol 2006; 107:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/106\">",
"      Ismail SK, Kenny L. Review on hyperemesis gravidarum. Best Pract Res Clin Gastroenterol 2007; 21:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/107\">",
"      Bolin M, Akerud H, Cnattingius S, et al. Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOG 2013; 120:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/108\">",
"      Togay-Iikay C, Yiit A, Mutluer N. Wernicke's encephalopathy due to hyperemesis gravidarum: an under-recognised condition. Aust N Z J Obstet Gynaecol 2001; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/109\">",
"      Spruill SC, Kuller JA. Hyperemesis gravidarum complicated by Wernicke's encephalopathy. Obstet Gynecol 2002; 99:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/110\">",
"      Erolu A, K&uuml;rk&ccedil;&uuml;olu C, Karaolanolu N, et al. Spontaneous esophageal rupture following severe vomiting in pregnancy. Dis Esophagus 2002; 15:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/111\">",
"      van Stuijvenberg ME, Schabort I, Labadarios D, Nel JT. The nutritional status and treatment of patients with hyperemesis gravidarum. Am J Obstet Gynecol 1995; 172:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/112\">",
"      Toriello HV, Erick M, Alessandri JL, et al. Maternal vitamin K deficient embryopathy: association with hyperemesis gravidarum and Crohn disease. Am J Med Genet A 2013; 161:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/113\">",
"      Schwartz M, Rossoff L. Pneumomediastinum and bilateral pneumothoraces in a patient with hyperemesis gravidarum. Chest 1994; 106:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/114\">",
"      Yamamoto T, Suzuki Y, Kojima K, et al. Pneumomediastinum secondary to hyperemesis gravidarum during early pregnancy. Acta Obstet Gynecol Scand 2001; 80:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/115\">",
"      Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am 2008; 35:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/116\">",
"      Mazzotta P, Maltepe C, Navioz Y, et al. Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada. Int J Gynaecol Obstet 2000; 70:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/117\">",
"      Smith C, Crowther C, Beilby J, Dandeaux J. The impact of nausea and vomiting on women: a burden of early pregnancy. Aust N Z J Obstet Gynaecol 2000; 40:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/118\">",
"      O'Brien B, Naber S. Nausea and vomiting during pregnancy: effects on the quality of women's lives. Birth 1992; 19:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/119\">",
"      Attard CL, Kohli MA, Coleman S, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol 2002; 186:S220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/120\">",
"      Nulman I, Rovet J, Barrera M, et al. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. J Pediatr 2009; 155:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/121\">",
"      Henderson BE, Benton B, Jing J, et al. Risk factors for cancer of the testis in young men. Int J Cancer 1979; 23:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/122\">",
"      Barker DJ, Eriksson JG, Fors&eacute;n T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002; 31:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/123\">",
"      Trogstad LI, Stoltenberg C, Magnus P, et al. Recurrence risk in hyperemesis gravidarum. BJOG 2005; 112:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/124\">",
"      Fejzo MS, Macgibbon KW, Romero R, et al. Recurrence risk of hyperemesis gravidarum. J Midwifery Womens Health 2011; 56:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/125\">",
"      Gadsby R, Barnie-Adshead AM, Jagger C. Pregnancy nausea related to women's obstetric and personal histories. Gynecol Obstet Invest 1997; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/126\">",
"      Czeizel AE, Dudas I, Fritz G, et al. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet 1992; 251:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/127\">",
"      K&auml;ll&eacute;n B, Lundberg G, Aberg A. Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. Acta Obstet Gynecol Scand 2003; 82:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/128\">",
"      Emelianova S, Mazzotta P, Einarson A, Koren G. Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. Clin Invest Med 1999; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/20/29002/abstract/129\">",
"      Gill SK, Maltepe C, Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can J Gastroenterol 2009; 23:270.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6811 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29002=[""].join("\n");
var outline_f28_20_29002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169438327\">",
"      GOAL OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21389041\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21389346\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Avoidance of triggers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acupuncture and acupressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Complementary and alternative medications (CAM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ginger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pyridoxine (vitamin B6)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antihistamines (H1 antagonists)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H217701\">",
"      Doxylamine succinate and pyridoxine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21389018\">",
"      SECONDARY APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H218237\">",
"      Women without dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H219543\">",
"      - First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H218526\">",
"      Antihistamines (H1 antagonists)",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H219195\">",
"      - Diphenhydramine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H219472\">",
"      - Meclizine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H218540\">",
"      - Dimenhydrinate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H219586\">",
"      - Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H218554\">",
"      Dopamine antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H218624\">",
"      - Prochlorperazine and chlorpromazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H219751\">",
"      - Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H88183937\">",
"      - Promethazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H218631\">",
"      - Droperidol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H218645\">",
"      Serotonin antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H30154769\">",
"      - Ondansetron",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H218715\">",
"      - Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H218723\">",
"      Acid reducing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H217940\">",
"      Women with dehydration, electrolyte abnormalities, acid-base abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21389638\">",
"      - Fluids and nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21389666\">",
"      Fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21389680\">",
"      Vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21389950\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21390012\">",
"      Oral and non-oral medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      REFRACTORY PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7475644\">",
"      Chlorpromazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7475442\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7475767\">",
"      Enteral and parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222950\">",
"      MANAGEMENT OF STABLE AND IMPROVING PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550221342\">",
"      Short-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550221006\">",
"      - Nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550221100\">",
"      - Hyperemesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550221285\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83690964\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6811|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/48/7941\" title=\"algorithm 1\">",
"      Algorithm for treatment of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6811|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/28/21956\" title=\"picture 1\">",
"      P6 acupressure point",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/7/4210?source=related_link\">",
"      Patient information: Hyperemesis gravidarum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/39/1650?source=related_link\">",
"      Patient information: Morning sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=related_link\">",
"      Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=related_link\">",
"      Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_20_29003="Outcome after BMT in beta thal";
var content_f28_20_29003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretransplant risk class and outcome in patients with beta thalassemia: pesaro experience",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Survival",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thalassemia-free survival",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transplant-related mortality",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrence of thalassemia",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        33&bull;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Values expressed in percent.",
"     <br>",
"      &bull; Among children in class 3, the incidence of recurrent thalassemia varied from 13 percent in those who received a full dose of cyclophosphamide (200 mg/kg) to 35 percent in those who received a lower dose (120 to 160 mg/kg).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29003=[""].join("\n");
var outline_f28_20_29003=null;
var title_f28_20_29004="Occurrence and age of onset in VHL";
var content_f28_20_29004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of von Hippel-Lindau disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ages at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common ages at dx",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency in patients CNS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CNS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinal hemangioblastomas",
"       </td>",
"       <td>",
"        0-68 yrs",
"       </td>",
"       <td>",
"        12-25 yrs",
"       </td>",
"       <td>",
"        25-60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endolymphatic sac tumors",
"       </td>",
"       <td>",
"        12-46 yrs",
"       </td>",
"       <td>",
"        24-35 yrs",
"       </td>",
"       <td>",
"        10-25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebellar hemangioblastomas",
"       </td>",
"       <td>",
"        9-78 yrs",
"       </td>",
"       <td>",
"        18-25 yrs",
"       </td>",
"       <td>",
"        44-72 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brainstem hemangioblastomas",
"       </td>",
"       <td>",
"        12-36 yrs",
"       </td>",
"       <td>",
"        24-35 yrs",
"       </td>",
"       <td>",
"        10-25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spinal cord hemangioblastomas",
"       </td>",
"       <td>",
"        12-66 yrs",
"       </td>",
"       <td>",
"        24-35 yrs",
"       </td>",
"       <td>",
"        13-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viscera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal cell carcinoma or cysts",
"       </td>",
"       <td>",
"        16-67 yrs",
"       </td>",
"       <td>",
"        25-50 yrs",
"       </td>",
"       <td>",
"        25-60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pheochromocytomas*",
"       </td>",
"       <td>",
"        4-58 yrs",
"       </td>",
"       <td>",
"        12-25 yrs",
"       </td>",
"       <td>",
"        10-20 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pancreatic tumor or cyst",
"       </td>",
"       <td>",
"        5-70 yrs",
"       </td>",
"       <td>",
"        24-35 yrs",
"       </td>",
"       <td>",
"        35-70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epididymal cystadenomas",
"       </td>",
"       <td>",
"        17-43 yrs",
"       </td>",
"       <td>",
"        14-40 yrs",
"       </td>",
"       <td>",
"        25-60 percent of males*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        APMO or broad ligament cystadenomas",
"       </td>",
"       <td>",
"        16-64 yrs",
"       </td>",
"       <td>",
"        16-46 yrs",
"       </td>",
"       <td>",
"        Estimated 10 percent of females",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes the 20 percent of lesions that occur outside the adrenal gland, also called paragangliomas.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Frequency of pheochromocytoma varies widely depending on genotype.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of, Dr. Eric Jonasch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29004=[""].join("\n");
var outline_f28_20_29004=null;
var title_f28_20_29005="Acute abdominal pain in children";
var content_f28_20_29005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acute abdominal pain in children by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neonate",
"       </td>",
"       <td class=\"subtitle1\">",
"        2 months-2 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        2-5 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        &gt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Colic",
"         </span>",
"        </p>",
"        <p>",
"         Dietary protein allergy",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Volvulus",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Necrotizing enterocolitis",
"         </span>",
"        </p>",
"        <p>",
"         Testicular torsion",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Adhesions",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Gastroenteritis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Viral illness",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Trauma (including inflicted injury)",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Incarcerated hernia",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Intussusception",
"         </span>",
"        </p>",
"        <p>",
"         Urinary tract infection",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Foreign body ingestion",
"         </span>",
"        </p>",
"        <p>",
"         Sickle cell syndrome vasoocclusive crisis",
"        </p>",
"        <p>",
"         Dietary protein allergy",
"        </p>",
"        <p>",
"         Tumor",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Hirschsprung disease",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Adhesions",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Hemolytic uremic syndrome",
"         </span>",
"        </p>",
"        <p>",
"         Toxin",
"        </p>",
"        <p>",
"         Meckel's diverticulum",
"        </p>",
"        <p>",
"         Hepatitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Gastroenteritis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Viral illness",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Trauma (including inflicted injury)",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Appendicitis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Pharyngitis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Constipation",
"         </span>",
"        </p>",
"        <p>",
"         Urinary tract infection",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Intussusception",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Foreign body ingestion",
"         </span>",
"        </p>",
"        <p>",
"         Sickle cell syndrome vasoocclusive crisis",
"        </p>",
"        <p>",
"         Henoch Sch&ouml;nlein purpura",
"        </p>",
"        <p>",
"         Ovarian torsion",
"        </p>",
"        <p>",
"         Intraabdominal abscess",
"        </p>",
"        <p>",
"         Tumor",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Adhesions",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Hemolytic uremic syndrome",
"         </span>",
"        </p>",
"        <p>",
"         Hepatitis",
"        </p>",
"        <p>",
"         Meckel's diverticulum",
"        </p>",
"        <p>",
"         Toxin",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Primary bacterial peritonitis",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Gastroenteritis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Viral illness",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Appendicitis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Trauma",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Constipation",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Pharyngitis",
"         </span>",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         Urinary tract infection",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Diabetic ketoacidosis",
"         </span>",
"        </p>",
"        <p>",
"         Sickle cell syndrome vasoocclusive crisis",
"        </p>",
"        <p>",
"         Henoch Sch&ouml;nlein purpura",
"        </p>",
"        <p>",
"         Ovarian torsion",
"        </p>",
"        <p>",
"         Testicular torsion",
"        </p>",
"        <p>",
"         Inflammatory bowel disease",
"        </p>",
"        <p>",
"         Intraabdominal abscess",
"        </p>",
"        <p>",
"         Ruptured ovarian cyst",
"        </p>",
"        <p>",
"         Cholecystitis",
"        </p>",
"        <p>",
"         Pancreatitis",
"        </p>",
"        <p>",
"         Urolithiasis",
"        </p>",
"        <p>",
"         Hepatitis",
"        </p>",
"        <p>",
"         Meckel's diverticulum",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Perforated ulcer",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Adhesions",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Hemolytic uremic syndrome",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Myocarditis, pericarditis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Primary bacterial peritonitis",
"         </span>",
"        </p>",
"        <p>",
"         Familial Mediterranean fever",
"        </p>",
"        <p>",
"         Abdominal migraine",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <span class=\"red\">",
"     Red: life-threatening.",
"    </span>",
"    <br>",
"     <span class=\"green\">",
"      Green: common.",
"     </span>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29005=[""].join("\n");
var outline_f28_20_29005=null;
var title_f28_20_29006="Frequency retained placenta by 3rd stage characteristics";
var content_f28_20_29006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Frequency of retained placenta by length and management of third stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Natural history of retained placentas with active and physiological management. Data on the natural history of the third stage are derived from the length of the third stage from the active versus control arms of trials of active management of labor, and the expectant management arms from trials of umbilical oxytocin as a treatment for retained placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Weeks SD. The retained placenta. Best Pract Res Clin Obstet Gynaecol 2008; 22:1103. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29006=[""].join("\n");
var outline_f28_20_29006=null;
var title_f28_20_29007="Right lung atelectasis CT";
var content_f28_20_29007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of right lung atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the chest with mediastinal window setting shows the rotational shift of the mediastinum to the right with complete opacification and loss of volume of the right lung. A small posteromedial pleural effusion is present (arrow) and is less dense than the adjacent collapsed lung. The effusion is probably due to the decreased relative pleural pressure in the right hemithorax following the collapse of the right lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_20_29007=[""].join("\n");
var outline_f28_20_29007=null;
